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High yields of RNA (e.g., mRNA, gRNA, lncRNA) are routinely prepared 
following a two-step approach: high yield in vitro transcription using T7 RNA polymerase, 
followed by extensive purification using gel or chromatic methods. In high yield 
transcription reactions, as RNA accumulates in solution, T7 RNA polymerase rebinds and 
extends the encoded RNA (using the RNA as a template), resulting in a product pool 
contaminated with longer than desired, (partially) double stranded impurities. Current 
purification methods often fail to fully eliminate these impurities which, if present in 
therapeutics, can stimulate the innate immune response with potentially fatal 
consequences. This study establishes novel in vitro transcription and purification 
technologies for high yield synthesis and purification of only encoded RNA.  
First, we demonstrate a simple and economical in vitro transcription method carried 
out under high salt with partially single stranded promoter DNA (pss[-5]). This inhibits all 
non-promoter specific activity, including RNA self-primed extension, and the system 
exclusively generates high yields of encoded RNA. Second, we establish a novel in vitro 
transcription system where promoter DNA and T7 RNA polymerase are co-tethered in 
proximity on beads to drive promoter binding and initiation, and high salt eliminates all 
 
x 
RNA product rebinding. The system is robust and reusable up to at least three times 
generating more yield of encoded RNA than conventional methods. Third, we develop 
novel affinity purification methods for in vitro transcribed RNA. Immobilized capture 
DNA selectively purifies only the desired RNA from a heterogeneous pool of products. In 
a novel approach, we improve binding capacity by increasing the binding sites per DNA 
oligo bound on beads using rolling circle amplification. We also introduce a universal 
capture DNA purification system that can capture any sequence of RNA without changing 
initial system components. Finally, we present a novel RNA microfactory that establishes 
the first flow in vitro transcription technology. In this new approach, encoded RNA is 
generated and continuously removed from the reaction chamber. This prevents primer 
extension and thus dramatically reduces double stranded impurities. By dramatically 
reducing extension of the desired RNA product, we achieve a high yield of relatively 
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 RNA therapeutics: a revolutionary class of drug transforming the field of medicine  
Traditional medicine uses small molecules or proteins as drugs that work by binding a 
target protein(1, 2). The patient usually has to take a cocktail of these drugs, most often very 
routinely, to exert the desired pharmacological effect. Each drug gets developed for a specific 
protein-small molecule or protein-protein interaction, and research findings from one treatment 
can often not be applied for another disease. These drugs also generalize diseases to be the same 
way for each patient, disregarding factors that may be unique to each case. In addition, the high 
dose administration requirement is simply daunting, and expensive.  
RNA therapies offer a novel class of drugs that have the potential to transform our 
understanding of medicine(3, 4). Messenger RNA (mRNA) translates the information from DNA 
into functional proteins (i.e. enzymes, growth factors). Therapies using silencing RNAs (siRNA) 
or microRNAs (miRNAs) target and bind host mRNA, to stop the translation for damaged proteins 
(5–8). Another approach in RNA therapies is to deliver mRNA directly into the cells (9, 10). This 
way, mRNA is used as replacement therapies to encode for a missing protein, or as vaccines to 
encode for a specific antigen. This is a powerful approach, since once the mRNA delivery platform 
is established, you can target any disease just by changing the sequence of the mRNA. 
RNA therapeutics have the potential to target many diseases from rare to common and 
have the benefit of customization for personalized treatments. Once a treatment is designed for a 
patient, dose administration may be significantly lower when compared with traditional drugs. 
Some approved RNA therapies in recent years have started generating profit (11–13), and 
as a result, RNA therapeutics companies have attracted increased investments and market 
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capitalization in the last 5 years. For example, three large mRNA therapeutics companies 
(Moderna Therapeutics, CureVac and BioNtech) attracted billions in investment in recent 
years. Moderna Therapeutics was valued at ~$7.6 billion in 2018, which was a record for a biotech 
IPO (12). Especially in 2020, with the promise of a COVID-19 vaccine, its market valuation went 
up to $40 billion. While Moderna has seen one of the most impressive surges, other biotech 
companies who work on establishing a COVID-19 vaccine have also seen ballooning in their 
market valuation (12). In the light of a new world order, paralyzed under the COVID-19 pandemic, 
the fast and efficient promise of mRNA technology has attracted more attention and investments 
to bring this powerful technology to the forefront of major medical needs. That is to be said, the 
field of RNA therapeutics has finally crossed the bridge from a “future promise” to a working 
technology for treating rare to common diseases.  
 The rise of mRNA therapeutics during the COVID-19 pandemic 
On January 11 of 2020, the whole genome sequence of a novel coronavirus (2019-nCoV) 
was shared by Chinese researchers. On March 11, the World Health Organization (WHO) declared 
COVID-19 a pandemic, warning of its likely (and rapid) spread throughout the world. Yet, even 
before this declaration, the possible global health emergency was recognized by many researchers 
and biotechnology companies. They responded quickly within their research directions and 
capabilities. 
Since then, over 130 vaccine candidates have been developed and mRNA-based vaccines 
were the frontrunners in the race to a vaccine (14)  There are two main reasons for this: speed and 
versatility of RNA therapeutics. To be more specific, within only two days of the publication of 
the 2019-nCoV sequence, Moderna Therapeutics and the National Institutes of Health (NIH) 
infectious disease research teams finalized the sequence of mRNA-1273, an mRNA vaccine, and 
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in record turnaround time in medical history, Moderna shipped the vaccine to NIH to start Phase 
1 clinical studies on February 24 (within 6 weeks of the sequencing) (15, 16). In addition to their 
strength in turnaround time, the versatility of the approach is attractive to establish a long-time 
platform, as opposed to a one-time fix. This is due to the fact that viruses change and mutate in 
response to drugs, and in traditional vaccines, a novel vaccine would have to be established for 
each mutated virus type. For mRNA vaccines and therapies, once the platform is well established, 
the system can be applied to a novel virus just by changing the sequence of the mRNA. 
The challenge, however, does not end by establishing an effective and safe mRNA vaccine. 
Once a vaccine is established, the next challenge is to manufacture billions of doses for the entire 
world, which is not a facile task. In fact, many of these companies working on establishing a 
vaccine have already made arrangements and collaborations for manufacturing, and even started 
manufacturing at some scale (17). Even if the mRNA vaccine sequence may eventually change, 
the financial risk was well taken by the government, to get a head start in the manufacturing process 
to produce billions of vaccines for the world. However, this was an emergency procedure and 
cannot be considered a feasible strategy for high yield production and distribution in the long term. 
 Generating large quantities of pure RNA for therapies 
Now that mRNA vaccines are at the forefront as a relief for the COVID-19 pandemic, there 
is a requirement of manufacturing high-quality vaccine for billions. It is essential to produce large 
quantities of RNA to be used in these vaccines, but the RNA also needs to be of high fidelity. In 
RNA therapeutics applications, in vitro transcription by T7 RNA polymerase is routinely used to 
synthesize for messenger RNA (mRNA) applications, for RNA interference studies (RNAi), or for 
the generation of guide RNA (gRNA, ≥100 bases) to be used in CRISPR (18–20). It can also be 
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used in basic RNA biology research (aptamers, splicing, riboswitches, CRISPR, lncRNA) and for 
nanotechnology(3, 12).  
 T7 RNA polymerase for in vitro transcription of RNA 
T7 RNA polymerase is an extensively studied, promoter specific and robust enzyme and 
the transcription of RNA in vitro is an established method to produce high yields of RNA of all 
sizes (21–25). T7 RNA polymerase binds its consensus promoter sequence with near nanomolar 
affinity in vitro (21, 26), initiates transcription at a unique site in the DNA, transitions to stable 
elongation, and runs off the end of a linear DNA template to synthesize the encoded RNA(24, 27–
29). In addition to the full-length encoded RNA, T7 RNA polymerase also produces short abortive 
RNAs 2-7 nt in length, intermediate RNAs shorter than the encoded length and RNAs longer than 
the encoded length (30, 31).  
 Origin of transcription byproducts by T7 RNA polymerase 
The formation of longer products has been reported in the past and different potential 
mechanisms for its generation have been proposed. These include templated and non-templated 
additions, cis or trans primed extension of RNA or strand jumping (20, 25, 30–32, 34, 36, 57–60, 
71–75, 98).  
Templated additions have been proposed to occur by product RNA having some self-
complementarity and extending itself from the 3’ end intra or intermolecularly. Intermolecular 
(trans) primed extension would occur by one RNA molecule sitting on another one and extending 
the first RNA from its 3’ end using the other RNA sequence as its template(36, 39). Intra (cis) 
primed extension occurs by product RNA looping back and sitting on itself, using its own sequence 
as the template for extension (31, 47). 
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In strand jumping (36), polymerase synthesizes encoded RNA using the template strand, 
but then is thought to jump to the nontemplate strand and continue, using the nontemplate strand 
as a template. This would result in the production of longer RNA, and if the conditions allow, can 
carry out multiple, sequential strand jumps to produce very long products. 
Our lab recently used RNA-seq (32) to demonstrate that in high yield transcription 
reactions, the most significant contribution to the longer, undesired RNA products is through the 
cis self-primed extension mechanism (31). In this mechanism, as high yields of encoded RNA 
accumulate in solution, mass action drives the polymerase to rebind the accumulated RNA at its 
3’ end and self-extend in a now promoter independent mechanism. The process is heterogeneous 
and distributive, leading to a diverse pool of products often abundant in (partially) double stranded 
RNAs longer than the encoded length.  
 The problem with long, double stranded impurities in RNA therapeutics applications 
In RNA therapeutics applications, using pure RNA is crucial in its safe administration in 
patients. Double stranded RNA is classified as a potent pathogen-associated molecular pattern in 
the body. Indeed, it has also been reported that in vitro transcription reactions can invoke the innate 
immune response, primarily via the double stranded impurities. Natural sensors like retinoic acid 
inducible gene (RIG-I) (48, 49), Toll-like receptor 3 (TLR-3) (50–53), protein melanoma-
differentiation-associated antigen 5 (MDA5) (48) may recognize the in vitro transcribed RNA and 
double stranded impurities and induce the innate immune response. Double stranded RNA can 
also inhibit translation through the activation and upregulation of protein kinase R (PKR) (54) or 




 Need for novel transcription and purification methods to generate high yields of pure 
RNA 
With the rise of the RNA therapeutics industry in recent years, production of large scale, 
high purity mRNA has been a challenge for many researchers and companies. There has been 
significant effort in establishing a superior RNA production method or device to generate large 
quantities of RNA in a robust yet inexpensive manner (56–59). Especially for in vitro transcription 
reactions of long RNAs, constant waste of template DNA has been the most significant cost factor. 
Some attempts have been made in recent years to improve in vitro transcription. One such method 
to generate RNA focuses on the prevention of cis primed extension activity of polymerase, 
resulting in a decrease in the longer double stranded impurities (47).  
Another approach, a bioreactor for in vitro batch transcription, has been filed as a patent 
by Curevac and Tesla Grohmann (57). In this batch approach, an ellipsoidal vessel, containing a 
magnetic bead immobilized template DNA holds a solution with transcription components, such 
as NTPs, T7 RNA polymerase and reaction buffer. Template DNA immobilized free floating 
magnetic particles are mixed by the moving of a magnet. This follows a batch reaction model, 
where repeated batch reactions reuse the same template DNA, saving on its cost. Another 
advantage of such a bioreactor, besides reusability of template DNA, is its scalability. However, it 
is important to note that this batch mode reaction does not aid in the prevention of longer impurities 
or other promoter non-specific activity of RNA polymerase. As a result, yields of the intended 
encoded product will often be low and products still need to go through extensive purification 
methods to reach desired purity and quality. 
Following in vitro transcription, it is common and essential to purify products using ion-
pair reversed-phase or other high performance liquid chromatography (HPLC) (49–53). It is also 
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possible to employ gel purification, but this method does not generally scale well, with good yield. 
While gel purification is arduous, time consuming, and impacts yield loss, HPLC purification is 
costly and results in a loss of yield as well. In addition, at long RNA lengths, the resolution in these 
separations becomes progressively worse, making the purification of the precisely encoded RNA 
unattainable. A recently developed method removes dsRNA impurities from the in vitro 
transcription pool by their selective binding to cellulose in an ethanol-based buffer (65). However, 
the effectiveness of this method is expected to depend on the relative lengths of double stranded 
regions and may remove desired RNAs with natively structured regions.  
A successful, high yield purification starts with a high-quality transcription reaction that 
does not produce an excess amount of shorter and longer byproducts from the get-go. As 
previously mentioned, high yield T7 RNA polymerase in vitro transcription often produces longer, 
undesired RNA byproducts as a result of the promoter independent cis self-primed extension 
activity. Therefore, one must first start by preventing this activity during transcription, in order to 
have a product pool high in yield of encoded RNA, so that they can be successfully purified post 
transcription in high yields. Furthermore, it is also essential to improve the current purification 
methodologies to adapt to the high pace requirement of RNA therapeutics field, and such method 
should be sequence selective, for the realization of extreme purity. 
 Objective of this study 
This study establishes novel in vitro transcription and purification approaches for high 
yield synthesis and purification of encoded RNA. Three distinct, novel transcription systems and 
devices described in chapters 2, 3 and 5 increase encoded RNA yield and purity by preventing cis 
primed extension activity of T7 RNA polymerase through various strategies. Chapter 4 sets the 
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foundations for a sequence specific affinity purification method for the purification of only 






IN VITRO TRANSCRIPTION USING TIGHT BINDING PROMOTER AT HIGH SALT 
PREVENTS CIS PRIMED EXTENSION ACTIVITY, WHICH NEARLY ELIMINATES 
LONGER, DOUBLE STRANDED IMPURITIES  
 
 INTRODUCTION 
T7 RNA polymerase is a promoter specific and robust enzyme used routinely to synthesize 
RNA of all sizes (20, 23, 66, 67). In addition to synthesizing encoded RNA at high yields, it also 
transcribes short RNAs (2-7 nucleotides) known as “abortives” (20, 37) and products longer than 
desired length (31, 39, 41, 47). T7 RNA polymerase has been reported to participate in an array of 
non-promoter driven activities including templated and non-templated addition (38), strand 
jumping (36) and cis or trans primed extension of product RNA (25, 31, 47, 68). Using RNA-seq 
of in vitro transcription products, our lab recently confirmed that a majority of the longer RNAs in 
high yield reactions stem from cis self-primed extension activity (31, 32). As high yields of RNA 
accumulate in solution, T7 RNA polymerase re-binds the product RNA and extends its 3’ end, 
using upstream RNA as its template (31, 32, 68). The process is heterogeneous and distributive 
and results in a product pool full of (partially) double stranded, longer than desired length RNAs. 
This results in large abundances of RNA incorrect in size, and often structure, complicating 
purification for end users.  
In RNA therapeutics applications, double stranded RNA (dsRNA) contamination is known 
to invoke the innate immune response, and dsRNA is known as a pathogen-associated molecular 
pattern in the body (69). Therefore, in vitro transcription is often followed up by extensive 
purification steps using gel or chromatographic methods (62, 63). These arduous methods often 
result in a loss of overall RNA yield, plus, if the product pool is mostly self-extended, most 
abundant product is often not the correct one. Purification methods that focus on the most abundant 
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product may be purifying the wrong product. Furthermore, in the generation of long RNA, such 
as mRNA, it is not possible to distinguish longer products that are only extended by 40 nt (in a 
1800 nt mRNA encoded product), for example, which although may be overlooked, can and will 
trigger the innate immune response! Therefore, to accurately prepare the desired, encoded RNA 
product, it is necessary to generate correct sequence and length RNA in the transcription reaction 
first. 
The purpose of this research is to establish a novel in vitro transcription method that inhibits 
product RNA rebinding, while fully retaining promoter driven transcription. We use a partially 
single stranded promoter DNA (pss[-5]), to favor promoter driven transcription, as this construct 
has at least four-fold tighter promoter binding relative to the fully double stranded construct (70). 
Strengthening promoter binding favors promoter driven transcription over product RNA 
rebinding. To further eliminate RNA rebinding activity in solution, we increase salt concentrations 
in solution without destroying promoter binding. This way, we hypothesize to generate only 
encoded RNA without the double stranded impurities at high yields. 
 MATERIALS AND METHODS 
2.2.1 Reagents  
DNA oligonucleotides used in transcription reactions were purchased from Integrated 
DNA Technologies (IDT). Sequences are shown in Table A1. All buffers were prepared and 
optimized for their specific use in house. High yield transcription buffer: 30 mM HEPES, 40 mM 
magnesium acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8. 
Pyrophosphatase (New England Biolabs, M2403L) was added to a final concentration of 10 
units/ml in all transcription reactions.  
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2.2.2 T7 RNA polymerase 
His-tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying 
the plasmid pBH161; purified and characterized as previously described (29).  
2.2.3 Transcription reactions 
All reactions were performed with house optimized and prepared high yield transcription 
buffer (as shown in Reagents) in the presence of 0.8 μM of nontemplate and template DNA, 0.8 
μM T7 RNA polymerase and 7.5 mM of each NTP in final volume of 20 μl at 37°C for 4 h. 
Transcription was stopped by heat denaturation at 95 °C for 5 min. 
2.2.4 Gel electrophoretic analyses 
Transcription reactions were labeled with [α-32P]ATP (PerkinElmer). All reactions were 
analyzed with 20% polyacrylamide, denaturing (7M urea) gel electrophoresis. Gels were imaged 
with a GE Typhoon FLA 9500 Phosphorimager. Quantifications of gel lanes were performed using 
ImageJ V 1.52s on raw TIF output.  
 RESULTS  
In this research, we use partially single stranded promoter DNA (pss[-5] DNA), where 
nontemplate strand is deleted downstream of position -5, to favor promoter binding over RNA 
product rebinding during in vitro transcription. T7 RNA polymerase binds this partially single 
stranded DNA four times tighter (Kd ≈ 1.1 nM) than the fully double stranded promoter DNA (Kd 
≈ 4 nM) (70). The tight binding of the pss[-5] DNA favors promoter-driven transcription over non-
promoter driven activities of polymerase. To further eliminate all RNA rebinding and extension 
activity, we increase added salt concentrations to reduce all RNA polymerase interactions while 
retaining strong promoter binding. High salt inhibits all nucleic acid enzyme interactions, but 
because we are starting with higher affinity, that reduction still allows good and stable promoter 
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binding. This way, only high yields of encoded RNA are synthesized, and double stranded 
impurities are reduced dramatically.  
2.3.1 Selection of a Promoter DNA For Exclusive Promoter-Driven Transcription 
at High Salt 
In the 23-base pair consensus T7 promoter, duplex recognition element stretches from -17 
upstream to -5 downstream position, while the AT rich melting region extends between the 
positions -4 and -1 (Figure 2.1A), as previously demonstrated in the two-domain model (71). Our 
lab has previously demonstrated that T7 RNA polymerase binds the fully double stranded promoter 
(herein will be called DS) tightly with a Kd of ≈ 4 nM (Figure 2.1B) (70). A partially singe stranded 
 
Figure 2.1. Scheme of consensus promoter sequence and polymerase binding domains. A. 
Consensus promoter DNA sequence shown in rectangular, and specific duplex recognition 
element (-17 to -5) and AT-rich melting region (-4 to -1) indicated. B. Promoter DNA sequences 
used in this study. DS and pss[+]2 possess, while pss[-5] lacks melting region, resulting in the 
higher affinity of pss[-5] for polymerase binding.  
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promoter DNA that extends only to +2 position downstream in the nontemplate strand (herein will 
be called pss[+2]) has a Kd similar to that of the fully double stranded promoter DNA (20, 72). As 
discussed above, this affinity can be strengthened using a partially single stranded promoter DNA 
that has no bases downstream of position -5 in the nontemplate strand (see pss[-5] in Figure 2.1B). 
While promoter binding affinities differ significantly between these constructs, transcription of the 
encoded product proceeds similarly on DS, pss[+2] or pss[-5] promoter DNA constructs (29).  
2.3.2 Exclusively promoter-driven transcription at high salt using pss[-5] promoter  
In the results shown in Figure 2.2, we compare high yield transcription reactions using 
three different promoters: DS, pss[+2] and pss[-5] under increasing concentrations of added NaCl. 
The template DNA in all reactions encodes for RNA-24, a sequence that is known to substantially 
participate in RNA 3’ extension activity (32). At low (no added) salt, fully double stranded (DS) 
promoter DNA produces the encoded RNA-24 and extended, double stranded impurities, as 
reported previously (32) and observed in Figure 2.2A. With increasing added salt, overall 
transcription decreases, with near complete inhibition by 0.3 M added salt. The pss[+2] construct, 
single stranded in the transcribed region, but double stranded in the melted region to +2, shows a 
product profile similar to that of the fully double stranded (DS) promoter construct under all salt 
concentrations, as shown in Figure 2.2A. 
In contrast, transcription using the more strongly binding pss[-5] promoter DNA shows a 
very different transcription profile. Increased strength of promoter binding is drives initiation to 
better compete with primer extension, and even at no added salt, the product profile does shift to 




Figure 2.2. Using pss[-5] promoter in high salt transcription dramatically reduces primer 
extension.  A) Salt dependence of transcription profiles for DS, pss[+2] and pss[-5] analyzed by 
20%, 7M urea denaturing gel electrophoresis, labeled via incorporation of [α-32P] ATP. The final 
concentrations of NaCl added to the standard reaction mixture are shown. B) Quantification of 
individual gel lanes in 2A. 
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Increased promoter binding affinity should also render initiation more resistant to 
increasing ionic strength. This is also readily observed in Figure 2.2. Increasing concentrations of 
added NaCl up to at least 0.2-0.3 M do not significantly decrease the yield of encoded length 24 
base RNA for pss[-5]. In contrast, and as expected, primer extension products decrease 
substantially.  
Data shown in Figure 2.2 clearly demonstrate that with increasing NaCl concentrations, 
the enzymatic activity is being pushed toward exclusively promoter-driven transcription with pss[-
5], and by 0.3 M added NaCl a very large majority of RNA rebinding activity is inhibited. As a 
result, a high yield of only encoded RNA is synthesized, while the double stranded primer 
extension impurities are dramatically reduced, including the n+1 product.  
2.3.3 Yield of encoded RNA is not affected by high salt using pss[-5] promoter 
To further substantiate that using partially single stranded promoter DNA (pss[-5]) during 
in vitro transcription renders promoter-directed initiation less sensitive to increased NaCl 
concentrations, we repeated the experiments above on another template. This template DNA 
encodes for RNA-24Alt, a sequence previously shown to not produce significant 3’ cis-primed 
extension (32). Figure 2.3A compares the encoded product yield of RNA-24Alt using pss[+2] and 
pss[-5] promoter DNA constructs under increasing NaCl concentrations. On pss[+2] promoter 
DNA, transcription initially increases at 0.1 M added NaCl. Although RNA-24Alt is reduced 
substantially in RNA-primed self-extension, this side reaction still occurs at a low rate, as 
evidenced by sensitive RNA-Seq assays (47), and as represented by a faint smear (in Figure 2.3A, 
or a “shoulder” in Figure 2.3B) migrating more slowly than the encoded 24mer at 0 M added NaCl. 
The ratio of this product to the encoded 24mer decreases with increasing salt, consistent with the 
results presented in Figure 2.1. Since transcription activity is redirected to promoter-driven 
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synthesis, the yield of the encoded RNA initially increases accordingly with added salt. Beyond 
about 0.1 M added NaCl transcription decreases with increasing salt concentration, more sharply 
for the pss[+2]reaction than for the pss[-5] reaction, as expected.  
 
Figure 2.3. Transcription is salt resistant using pss[-5].  A) Salt dependence of transcription 
profiles using pss[+2] and pss[-5] template DNA encoding RNA-24Alt, analyzed as in Figure 2.2. 
B) Quantification of individual lanes in 3A. 
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The observation that net yield of correct length product begins decreasing at lower 
concentrations of NaCl for template 24Alt than for template 24, reflects the large reduction in 
primer extension in the former. It is reasonable to conclude that initiation begins to slow (promoter 
binding decreases) similarly for both constructs, but in the case of template 24, the net yield of 
encoded length product increases initially, as encoded length product is chased less to longer, self-
primed extensions. The concentration of added NaCl that yields maximal full-length product will 
likely be a function of RNA sequence and should be determined empirically for different RNAs. 
This shows that even RNA sequences that are observed to not substantially participate in 
primer extension can have longer impurities that cannot easily be observed in gel analyses. Figure 
2.3 further proves that in vitro transcription using pss[-5] promoter DNA at high salt yields very 
pure encoded RNA without compromise to yield. In summary, while overall RNA yield is affected 
at a small degree, the encoded RNA yield and purity is significantly superior at 0.3 M added NaCl 
using pss[-5] promoter DNA during high yield in vitro transcription reaction, when compared with 
0 M NaCl using pss[+2] promoter DNA. 
2.3.4 Generality of the solution 
Different RNA sequences have different 3’ cis self-extension rates. In Figures 2.2 and 2.3 
we focused on two RNAs of same size, but with different sequences, RNA-24 and RNA-24alt. 
Both showed the expected improvements from transcription with pss[-5] constructs at elevated salt 
concentrations. To demonstrate the universality of this system for synthesis of clean RNA of most 
any size and sequence, we selected two other RNA that are longer in size and have distinct 
sequences from each other. We generated a 34 nt RNA (RNA-34) by taking the RNA-24 sequence 
used in Figure 2.2 and inserting 10 bases at position +8. Since RNA-24 and RNA-34 have the 
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same 3’ terminal sequences, we expected them to behave similarly in primer extension, 
independent of RNA length.  
 
Figure 2.4. Generality of solution on other RNA. A. Low and high salt transcription profiles for 
pss[+2] and pss[-5] DNA encoding for RNA-34 and RNA-40,analyzed as in Figure 2.2. 
We also designed a completely different RNA sequence (RNA-40), 40 bases in length, that 
participates in 3’ cis extension at a rate much less than RNA-24, but slightly more than does RNA-
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synthesis of each of RNA-34 and RNA-40, the use of a pss[-5] promoter at 0 M added salt increases 
polymerase affinity to promoter DNA over RNA rebinding, resulting in the production of 
increased encoded RNA relative to longer impurities. Further increasing the added salt 
concentration to 0.4 M NaCl slightly drops the overall yield, but gives high purity of encoded 
product, as previously observed in Figures 2.2 and 2.3.  
 DISCUSSION  
In this research, we have developed a novel, high yield in vitro transcription approach that 
favors promoter-driven transcription and limits the RNA-rebinding and cis primer extension 
activity that leads to dsRNA impurities. Pss[-5] promoter DNA has at least four times higher 
binding affinity for T7 RNA polymerase and drives most T7 RNA polymerase activity to 
promoter-driven transcription. Increased salt concentrations in solution further inhibit RNA 
rebinding activity almost completely, with minimal impact on promoter-driven transcription. 
Results show only encoded RNA is produced with significantly improved purity without 
significant loss in yield. 
2.4.1 Using pss[-5] DNA drives promoter driven transcription over cis primed 
extension 
As expected, high yield transcription using pss[-5] DNA favors promoter binding over 
product RNA rebinding, and results in a complete shift in the transcription profile. Increasing salt 
concentrations result in the complete inhibition of enzymatic activity when using DS and pss[+2] 
DNA, as shown in Figure 2.2. Using system pss[-5] DNA, high salt further inhibits cis-primed 
extension activity of T7 RNA polymerase, while allowing promoter-directed transcription to 
continue as before, as shown in Figure 2.2. This results in a near complete elimination of the 
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longer, double stranded impurities. Since the longer products would have been converted from 
encoded-length RNAs, this also results in an overall increase of the desired RNA yield. 
Further inspection of the gel data may reveal deeper understanding of RNA rebinding 
behavior. Previous findings had strong evidence that even n+1 products are produced by re-binding 
of full length (or shorter) RNA, followed by RNA-templated addition of one (or more) bases (47). 
Analysis of the traces and quantification profiles in Figure 2.2A and 2.2B, respectively, for the 
pss[-5] promoter lanes reveals tentatively assigned n and n+1 products at 0 M added NaCl. As the 
salt concentration increases, the n+1 length product disappears relative to the n length product. 
Interestingly, an apparent n length product is a larger fraction of the total at the highest salt 
concentrations. It is possible that at low salt concentrations, n products are being chased to longer 
lengths, a process which disappears at the highest salt levels.  
2.4.2 Transcription using pss[-5] template DNA is salt resistant 
In order to characterize the salt resistance of transcription using the pss[-5] promoter DNA, 
we used a sequence, RNA-24Alt, previously observed to participate in cis primed extension at a 
rate much less than RNA-24. Figure 2.3 shows that while all transcription activity gets inhibited 
with increasing added salt for pss [+2], RNA-24Alt yield is retained up to 0.3-0.4 M salt using 
pss[-5]. At 0.1 M NaCl, the yield of encoded RNA-24Alt increases using both pss[+2] and pss[-5] 
template DNAs. This is due to the fact that at 0 M NaCl, some encoded RNA participates in cis 
primed extension activity, but at a much lower rate an in a more heterogeneous manner that results 
in dispersed longer length RNA impurities. This observed increase in encoded RNA yield 
decreases for pss[+2] with increasing added salt, but is retained using pss[-5] up to 0.3-0.4 M NaCl. 
At 0.4 M NaCl, the overall yield starts to drop, as high salt inhibits all enzymatic activity, as 
observed in Figure 2.2.  
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2.4.3 Generality of the solution 
We confirmed our initial hypothesis using templates that encoded for very short RNA. 
Since all long RNAs are generated using in vitro transcription using T7 RNA polymerase, or one 
of its close relatives, we also tested the solution to encode longer RNA with different sequences. 
We demonstrated in Figure 2.4, that using pss[-5], RNA-34 and RNA-40 were generated at higher 
purity at 0.4 M added salt concentrations. In transcription reactions where template DNA is 
synthetic, it is possible to exchange the nontemplate strand used with the short nontemplate used 
in pss[-5] constructs. However, for plasmid DNA or linearized long RNA, since double stranded 
template DNA is a given in these scenarios, this solution may not be possible to use in already 
double stranded long template DNAs encoding for RNA.  
2.4.4 Some polymerase falls of in the transition to elongation due to tight promoter 
binding  
Pss[-5] DNA favors promoter binding over product RNA rebinding, since this promoter 
DNA does not have the AT rich melting region. Polymerase has contacts with the duplex upstream 
of position -5 in promoter, whereas downstream of position -4, polymerase only interacts with the 
template (72). Using pss[-5], we completely remove the requirement for DNA melting, resulting 
in the recovery of a portion of the polymerase binding energy that would have otherwise went to 
melting of the AT rich melting region. The observation of increased 12-15 nt intermediate products 
while transcribing full length RNA using pss[-5] , as shown in Figures 2.2, 2.3, 2.4, 2.5 suggests 
strong binding with the promoter recognition region in promoter DNA may impair (but not 
destroy) the transition to elongation. On the contrary, using pss[+]2 or DS DNA, no such 
intermediates are observed. A behavior similar to this was previously observed by Martin lab. In 
that work, Esposito covalently linked promoter DNA to the polymerase for transcription (73). In 
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that work, while initiation was observed to not suffer, as expected, only 25% of the initiated 
population proceeded to elongation and follows through to the formation of full-length encoded 
RNA. In that work, there was a similar observation of increased 12-15 nt intermediate products 
that could be a result of the short covalent linkage used in this earlier system. On contrast, in the 
system introduced in this chapter, we see most of the initiated population to proceed to full 
elongation and falloff, resulting in high yields of encoded RNA production. Nevertheless, the gel 
migration of 12-15 nt intermediate products are nowhere near the encoded RNA length (unlike cis 
prime extended RNA products); their separation from the encoded RNA in a purification step 
should be relatively straightforward.  
 SUMMARY 
In this research, we demonstrate a novel in vitro transcription method as a solution to the 
double stranded impurities observed in high yield transcription reactions. With this system, T7 
RNA polymerase activity is driven to be much more promoter specific, and under increased salt 
concentrations, all other non-promoter specific activity, including RNA self-primed extension is 
inhibited. The system is easy to implement, robust and economical. There is reason to expect the 
system to be able to produce longer RNA, since it has demonstrated ability for efficient promoter 
clearance. It is important to note that although longer, double stranded impurities are prevented 
from being generated using this methodology, system results in short RNA products of 12-15 nt 
in size. While these RNAs are easily distinguishable by most RNA products longer than 20 nt in 
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HIGH SALT TRANSCRIPTION WITH DNA AND T7 RNA POLYMERASE CO-
TETHERED TO BEADS GENERATES INCREASED YIELDS OF HIGHLY PURE RNA 
 
3.1 INTRODUCTION 
Our understanding of RNA’s central role in biology continues to expand and be exploited. 
Researchers across a wide swath of basic science and applied technologies require high yields of 
pure RNA. Solid phase chemical synthesis can, in principle, generate RNAs up to 50-100 nt in 
length, but both yield and purity decrease with increasing lengths (74–76). Enzymatic synthesis in 
vitro by T7 RNA polymerase is widely used to synthesize high yields of RNA of all lengths for 
structural studies, basic RNA biology (splicing, riboswitches, CRISPR, lncRNA), therapeutics 
applications (mRNA vaccines and therapies, siRNA, gRNA for CRISPR) and nanotechnology (18, 
20, 23, 66).  
T7 RNA polymerase binds its consensus promoter sequence with near nanomolar affinity 
in vitro (70, 77), initiates transcription at a unique site in the DNA, transitions to stable elongation, 
and runs off the end of a linear DNA template to synthesize the encoded RNA (18, 20, 28). It has 
long been known that in addition to the full-length encoded RNA, T7 RNA polymerase produces 
short abortive RNAs 2-7 nucleotides in length (20, 78) and RNAs longer than the encoded length. 
These longer products have been proposed to be generated through templated and non-templated 
additions (20, 38–40), cis or trans primed extension of RNA (25, 31, 34, 41–45), or strand jumping 
(36). Our lab recently demonstrated that in high yield transcription reactions, the most significant 
contribution to the longer, undesired RNA products is through the cis self-primed extension 
mechanism (31, 32). As high yields of encoded RNA accumulate in solution, mass action drives 
the polymerase to rebind the accumulated RNA at its 3’ end and self-extend via a non-promoter 
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dependent mechanism. The process is heterogeneous and distributive, leading to a diverse pool of 
products often abundant in (partially) double stranded RNAs longer than the encoded length.  
In RNA therapeutics applications, dsRNA contamination from in vitro synthesized RNA 
can invoke the innate immune response, as dsRNA is classified as a potent pathogen-associated 
molecular pattern in the body. This can happen by way of activating natural sensors like retinoic 
acid inducible gene (RIG-I) (48, 49), Toll-like receptor 3 (TLR-3) (50, 52, 53) and protein 
melanoma-differentiation-associated antigen 5 (MDA5) (48). It can cause the production of type I 
interferon, which can inhibit translation through the activation and upregulation of protein kinase 
R (PKR) (54). It can also cause cellular mRNA degradation by activating the 2’-5’ oligoadenylate 
synthetase (OAS) enzyme family (55). Therefore, therapeutics researchers must follow up in vitro 
T7 RNA polymerase transcription with often very extensive purification methods (60–64). Gel or 
chromatic (HPLC) purification methods are time consuming, result in a loss of yield, and are 
imprecise, as the encoded product may not always be readily identified. At long RNA lengths, the 
resolution in these separations becomes progressively worse, making the purification of the 
precisely encoded RNA unattainable. A recently developed method removes dsRNA impurities 
from the in vitro transcription pool by their selective binding to cellulose in an ethanol-based buffer 
(65). However, the effectiveness of this method is expected to depend on the relative lengths of 
double stranded regions and may remove desired RNAs with natively structured regions. 
Although researchers have long focused on improving the overall yield of in vitro 
transcription reactions, we have confirmed with RNA-Seq that the very conditions of high yield 
synthesis often drive the correct product into primer extended, double stranded impurities (32). 
This not only impacts the overall purity, but also the yield of the encoded RNA.  
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In this research, we present a novel method of in vitro transcription that allows promoter-
directed transcription while preventing primer extension activity, thereby dramatically reducing 
double stranded impurities. In brief, by increasing salt concentrations in solution, we reduce all 
protein-nucleic acid interactions. To selectively restore promoter binding, we tether both T7 RNA 
polymerase and promoter DNA to a solid support (beads). This drives their association even at 
high salt concentrations. Near elimination of RNA rebinding and extension not only results in a 
dramatic reduction in longer, primer-extended products, but also nets a dramatic increase in the 
yield of encoded RNA. 
3.2 MATERIALS AND METHODS 
3.2.1 Reagents  
DNA oligonucleotides used in transcription reactions were purchased from Integrated 
DNA Technologies (IDT). Sequences with modifications are shown in Table A2. Unless otherwise 
noted, all transcription reactions were performed using partially single-stranded DNA constructs 
where the nontemplate DNA extends to the +2 position downstream of the promoter sequence 
(referred to here as pss[+2]). This promoter DNA construct is known to have the same functionality 
as fully double stranded promoter DNA (20, 72) and we have found in these studies that it behaves 
identically to fully double stranded DNA with respect to salt. The following buffers were 
optimized in house and used where indicated. High yield transcription buffer contained final 
concentrations of 30 mM HEPES, 40 mM magnesium acetate, 25 mM potassium glutamate, 0.25 
mM EDTA, 0.05% Tween20, pH 7.8, 10 units/ml pyrophosphatase (New England Biolabs). Wash 
buffer contained 0.5 M NaCl, 20 mM Tris-HCl (pH 7.5), 1 mM EDTA. Storage buffer contained 
30 mM HEPES, 15 mM magnesium acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05% 
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Tween20, pH 7.8. Nucleoside triphosphates (New England Biolabs) were added to transcription 
reactions at final concentrations of 7.5 mM each. 
3.2.2 T7 RNA polymerase 
His tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying 
the plasmid pBH161; purified and characterized as previously described (29).  
3.2.3 Strep-T7 RNA polymerase 
ATG start codon, Strep-tag® II sequence (WSHPQFEK) and a linker sequence (GGS) were 
(followed by the T7 RNA polymerase gene) inserted between the Nco I and Hind III restriction 
sites in the plasmid vector pBAD HisA. Strep tagged T7 RNA polymerase was expressed under 
the inducible control of the L(+) arabinose promoter, and further purified using Strep-Tactin® 
protein purification resin from IBA technologies.  
3.2.4 Untethered transcription reactions 
All reactions were performed with high yield transcription buffer in the presence of 0.8 μM 
(each) of nontemplate and template DNA, 0.8 μM T7 RNA polymerase and 7.5 mM of each NTP, 
in an overall 10 or 20 μL reaction volume at 37 °C for 4 h. Transcription was stopped by heat 
denaturation at 95 °C for 5 min.  
3.2.5 Tethered transcription reactions 
To assemble the promoter complex, equimolar (0.8 µM) concentrations of biotinylated 
nontemplate DNA, template DNA and Strep-T7 RNA polymerase were incubated at 4 °C for 30 
min. Strep-Tactin®XT (5% slurry) beads were washed with storage buffer three times and then 
incubated with the above enzyme-promoter complex at 4 °C overnight to form the tethered 
transcription system. Tethered transcription reactions contained the equivalent of 0.13 μL dry 
beads per 10 μL reaction (0.26 µL for 20 μL reactions). Before each transcription reaction, the 
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tethered transcription system was washed twice with wash buffer and once with storage buffer. 
Transcription was initiated by the addition of high yield transcription buffer (containing additional 
NaCl where indicated) with 7.5 mM of each NTP, in a final reaction volume of 10 or 20 μL at 37 
°C for 4 h. After 4 h, the supernatant was separated from the beads and heat denatured at 95 °C for 
5 min. 
3.2.6 Reuse of the tethered complex for transcription reactions 
For the re-use reactions of Figure 5, transcription was carried out at 37 °C for 2 h. As indicated 
below, partially single stranded promoter DNA with a nontemplate strand that extends only to +2 
position downstream (pss[+2]) or a partially single stranded promoter DNA with a nontemplate 
strand that extends only to -5 position downstream (pss[-5]) were used for Figures 5B and 5C, 
respectively. After the first reaction was complete, the supernatant carrying the transcription 
products was separated from the beads and processed for gel quantification. The second reaction 
was then initiated as above, with the addition of fresh high yield transcription buffer and NTPs and 
carried out at 37 °C for 2 h. This process was repeated for a third time.  
3.2.7 Gel electrophoretic analyses 
All transcription reactions, except the reusability reactions shown in Figure 5, were labeled 
with [α-32P]ATP (PerkinElmer). The gel showing reusability reactions in Figure 5 was stained with 
SYBR Gold Nucleic Acid Gel Stain (Invitrogen). All reactions were analyzed by 20% 
polyacrylamide (19:1 acrylamide:bisacrylamide) denaturing (7M) urea gel electrophoresis. Gels 
labeled with radioactivity were dried and then imaged with a GE Typhoon FLA 9500 
Phosphoimager. Gels labeled with SYBR Gold stain were imaged directly with a Bio-Rad Gel Doc 
Go Imaging System Blue Tray. Quantifications of gel lanes were performed using Fiji (79) 




The goal of this study is to eliminate RNA product rebinding and subsequent extension 
activities of T7 RNA polymerase, while retaining promoter-directed transcription. Like almost all 
protein-nucleic acid interactions, both initial binding of T7 RNA polymerase to its promoter and 
rebinding of product RNA are stabilized in part by electrostatic interactions between positively 
charged residues on the RNA polymerase surface and the negatively charged phosphate backbone 
of the DNA or RNA (22, 24, 80, 81). As a result, increasing salt concentrations should destabilize 
both promoter DNA binding and product RNA rebinding. We have previously shown that 
covalently crosslinking an engineered cysteine (A94C) in the N-terminal domain of T7 RNA 
polymerase to a 3’ thiol-modified template DNA creates a locally high concentration of the 
promoter near its binding site, allowing promoter binding, even at high salt (73). Initiation 
proceeds well and at least some of these complexes transition to the stable elongation phase (73). 
Elongation by T7 RNA polymerase is stabilized by the topological locking of the RNA around the 
template DNA in the enzyme active site (28) and elongation has been shown to be resistant to 
added salt concentrations up to at least 0.2 M NaCl (81, 82). 
By tethering T7 RNA polymerase to its DNA promoter and carrying out transcription at 
elevated salt concentrations, we can achieve promoter-initiated transcription while preventing 
product RNA rebinding that otherwise would lead to cis primed extension activity. We expect this 
approach to reduce substantially the production of longer, double stranded RNA impurities. 
3.3.1. Design of a Tethered in vitro Transcription System  
In order to tether the polymerase to the promoter DNA and still allow functional initiation 
and substantial transition to elongation, we bound each, independently to Strep-Tactin®XT 
magnetic beads, as shown in Figure 3.1. The N-terminal domain of T7 RNA polymerase (together 
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with a hairpin loop from the C-terminal domain) forms the promoter binding platform (83, 84) and 
many N-terminal fusions of T7 RNA polymerase function well in promoter-directed transcription 
(85–87). Thus, we fused the Strep-tag® II peptide (WSHPQFEK), followed by a short and flexible 
peptide linker (GGS), to the N-terminus of recombinant T7 RNA polymerase (88). Herein, we will 
call this Strep-tagged variant Strep-T7 RNA polymerase. The Strep-tag® II peptide has nanomolar 
binding affinity to specifically engineered Strep-Tactin®XT coated magnetic beads (89). We also 
used 5’-biotinylated nontemplate DNA to independently bind the promoter DNA to the Strep-
Tactin®XT beads. Biotin is reported to have picomolar binding affinity to Strep-Tactin®XT coated 
magnetic beads (89).  
 
Figure 3.1. Crosslinked transcription complex. T7 RNA polymerase containing an N-terminal 
Strep-tag® II peptide and duplex DNA labeled with biotin at the 5’ end of the nontemplate 
strand are bound to (tetravalent) Strep-Tactin®XT coated magnetic beads. 
To confirm that the Strep-tag® II peptide addition at the N-terminus of T7 RNA polymerase 
does not affect transcription activity, we performed in vitro transcription reactions using Strep-T7 
RNA polymerase and promoter DNA (without a biotin tag) encoding a 24 base RNA (RNA-24) 
under high yield transcription conditions. The gel analysis in Figure 3.2 demonstrates identical 
transcription profiles using T7 RNA polymerase and Strep-T7 RNA polymerase. This confirms 
















polymerase. Similarly, biotinylating the upstream end of the promoter has no effect on promoter 
function, as also shown in Figure 3.2. Finally, we tested these constructs for transcription activity 
at 0.4 M added NaCl and, as expected for the uncoupled species, observed essentially complete 
inhibition of transcription in all constructs. 
 
Figure 3.2. Effect of Strep Tag® II and nontemplate biotinylation on high yield solution 
transcription of RNA-24. A. Denaturing gel analysis (20%, 7M Urea) of high yield transcription 
of RNA-24 using the corresponding constructs. B. Quantitative analysis of gel in A. 
3.3.2. Tethered system favors promoter-directed transcription at high salt  
Having demonstrated that the DNA and protein modifications do not perturb promoter 
binding and transcription, we proceeded to test the co-tethered system for function. Given that at 



































































(70) we first pre-incubated the 5’-biotinylated nontemplate strand, template strand encoding a 24 
base RNA and Strep-T7 RNA polymerase at final equimolar concentrations, as described in the 
Methods section. We then incubated the assembled promoter complex with tetrameric Strep-
Tactin®XT coated magnetic beads to form the tethered in vitro transcription system illustrated in 
Figure 3.1.  
While elevated salt concentrations weaken both promoter binding and RNA rebinding 
activities of T7 RNA polymerase, indirectly tethering the polymerase to the promoter (as 
demonstrated in Figure 3.1) should restore promoter binding by increasing the local concentration 
of promoter DNA compared to free RNA in solution, as observed previously using a direct 
tethering approach (73). To test the hypothesis with our tethered in vitro transcription system, we 
performed a comparative analysis of transcription between tethered and untethered systems as a 
function of increasing concentrations of added NaCl. In order to see the direct effect on cis primed 
extension activity, we selected a template strand that encodes a 24 base RNA (RNA-24) known to 
serve effectively in 3’ self-extension (32). The gel analysis presented in Figure 3.3A shows that as 
added NaCl concentration is increased from 0 M to 0.4 M in 0.1 M intervals, all transcription 
activity decreases for the untethered system, and is negligible at 0.4 M added NaCl. In the tethered 
system, promoter binding (and transcription) is relatively resistant to increasing concentrations of 
added salt, as expected. The data also confirm that product RNA rebinding to polymerase is 
inhibited, as there is a dramatic reduction in the formation of primer extension products. At 0.3 M 
added NaCl, most of the primer extension activity is inhibited, leading directly to an increase in 
the encoded RNA yield. At 0.4 M added NaCl, the overall yield is decreased somewhat relative to 
that at 0.3M, but the purity of the encoded RNA is at its highest (and the concentration of the 
encoded RNA is substantially higher than in the untethered control). Overall, the tethered 
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transcription system under high salt produces significantly improved purity and increased yield of 
the correct length product. 
 
Figure 3.3. Tethered, high salt transcription dramatically reduces primer extension.  A. Salt 
dependence of transcription profiles for untethered and tethered complexes analyzed by 20%, 
7M urea denaturing gel electrophoresis, labeled via incorporation of [α-32P] ATP. The final 
concentrations of NaCl added to the standard reaction mixture are shown. B. Quantification of 
individual gel lanes in 3.3A. 
3.3.3. Synthesis of encoded RNA is not impaired by tethering  
Not all encoded RNAs participate in 3’ self-extension (32). To confirm that the described 
tethering does not have an effect on the fundamental efficiency of promoter-directed transcription, 
we repeated the above comparative analysis with a template strand encoding another 24 base RNA 
(RNA-24Alt) that is known not to participate substantially in 3’ self-extension (32). For the 
untethered system, gel analysis of the products presented in Figure 3.4A (and quantified in 3.4B) 
shows an overall loss of yield in RNA transcription with increasing added NaCl concentration, as 
expected (more subtly, there is an initial increase in 24 base RNA at 0.1 M added NaCl, which 
then decreases to barely detectable levels by 0.4 M added NaCl). 
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In contrast, Figures 3.4A and 3.4B show that the tethered system, while also initially 
showing an increase in the yield of 24 base RNA with increasing NaCl, continues to transcribe 
well up to at least 0.3 M added NaCl, and produces more 24 base RNA at 0.4 M than at 0 M added 
NaCl. Close inspection of the gel lanes in Figure 3.4A suggests that the RNA-24Alt sequence is 
in fact producing primer extended products at 0 M added NaCl, as evidenced by a broad smear 
above the 24 base RNA band that decreases with increasing NaCl. Quantification of the extended 
products is shown in gray at 10X magnification in Figure 3.4B to better depict this observation. 
Thus, even for this construct, the intensity of the 24 base RNA band underestimates the total RNA 
produced. According to the model, inhibition of the primer extension that produces the broad 
smear would result in higher net amounts of the initially synthesized 24 base RNA, as observed.   
 
Figure 3.4. Transcription by tethered complexes is salt resistant.  A) Salt dependence of 
transcription profiles for untethered and tethered complexes encoding RNA-24Alt, analyzed as 
in Figure 3.3. B) Quantification of individual lanes in 3.4A. Extended products shown in gray at 
10X magnification.  
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3.3.4. Generality of the system 
The results presented in Figures 3.3 and 3.4 use DNAs encoding 24 base RNAs with 
different sequences. To further test the generality of this system, we took the RNA-24 template 
sequence introduced in Figure 3.3 and inserted 10 bases at position +8 to yield DNA that encodes 
a 34 base RNA (RNA-34), as shown in Table A2. Paralleling the experiment of Figure 3.3, we 
compare in Figure 3.5 untethered and tethered transcription of RNA-34 at low (0 M) and high salt 
(0.4 M) added NaCl concentrations. As predicted by the general model, the tethered in vitro 
transcription system produces primarily the encoded 34 base RNA at high salt. This result confirms 
that the system can be used for RNA of longer lengths to generate high yields of encoded RNA 
while preventing the formation of self-extended longer RNA impurities. 
 
Figure 3.5. Improvements are independent of RNA length.  A) Low and high salt transcription 
profiles for tethered and untethered complexes analyzed as in Figure 3.3. B) Gel quantification 










































3.3.5. Biotinylated DNA and Strep-T7 RNA polymerase bind at nearby tetrameric 
sites  
To encourage both enzyme and DNA to attach to the same Strep-Tactin®XT tetramer in 
the above experiments, we preincubated (at low salt) Strep-T7 RNA polymerase and biotinylated 
promoter DNA before adding the Strep-Tactin®XT magnetic beads. Following assembly, a high 
salt wash was used to remove components (free polymerase and DNA) not strongly bound to the 
beads. As controls, we prepared tethered transcription complexes using DNA and T7 RNA 
polymerase with only one or neither of the two modifications. The resulting in vitro transcription 
reactions with DNA encoding RNA-24 under high yield conditions, shown in Figure 3.6, confirm 
that the absence of one or both of the modifications destroys RNA synthesis, both at low and high 
salt concentrations, as expected.  
 
Figure 3.6. Effect of Strep Tag® II and nontemplate biotinylation on high yield tethered 
transcription of RNA-24. A. Denaturing gel analysis (20%, 7M Urea) of high yield transcription 
























































Despite the high affinity of T7 RNA polymerase for its promoter, and the strategic pre-
forming of the promoter complex before tethering to the beads, we expected that some enzyme 
might couple to beads lacking nearby DNA or vice versa. Without a partner, on well-washed beads, 
these species should be inactive in transcription. To test for enzyme immobilized without a 
promoter DNA partner, we challenged an assembled and washed system encoding RNA-24Alt by 
introducing in solution unmodified promoter DNA encoding RNA-34Alt. At low salt, RNA 
polymerase without a locally (and functionally) tethered 24-Alt DNA partner should bind the free 
34-Alt DNA and synthesize a 34 base RNA. The results in Figure 3.7 demonstrate this hypothesis 
to be correct. While at low salt, both 24 base and 34 base RNAs are produced at levels similar to 
that of untethered transcription, at high salt, only the 24 base RNA from the tethered DNA template 
is observed.  
 
Figure 3.7. Challenging the Tethered System with Untethered Promoter DNA. A) Denaturing 
gel analysis (20%, 7M Urea) of high yield transcription of untethered RNA-24Alt and untethered 
RNA-34Alt and tethered RNA-24Alt and untethered RNA-34Alt at low and high salt 

















































To further confirm that (RNA-34-encoding) DNA-34 is binding to and reacting with 
enzyme lacking a DNA partner, we increased the ratio of labeled 24 base encoding DNA-24 to 
protein from 1:1 to 2:1, followed by a high salt wash to remove all unbound DNA. The results 
shown in Figure 3.8 reveal an approximately two-fold increase in the overall RNA-24Alt 
production for the 2:1 prep compared with the 1:1 prep, while RNA-34Alt production decreases 
only slightly. This suggests that under these conditions, a significant portion of enzyme bound to 
beads may not have a functionally tethered DNA nearby. Alternatively, biotinylated DNA-24 
could be binding to an empty binding site in the tetramer, further increasing the DNA concentration 
near tethered polymerase. Future development in this system will focus on optimizing binding 
capacity. 
 
Figure 3.8. Saturating the free tethered enzyme with modified promoter DNA. A) Denaturing 
gel analysis (20%, 7M Urea) of high yield transcription of tethered RNA-24Alt and untethered 
RNA-34Alt from 1:1 and 1:2 E:D preincubation. B) Quantitative analysis of gel in A. 
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3.3.6. Use of tight binding pss[-5] and added salt allows in tethered transcription  
The above demonstrates that enzyme bound to beads can transcribe from promoter DNA 
free in solution, and that increasing salt concentrations in the transcription reaction results in a 
preferential inhibition of enzymatic activity from free DNA over that from DNA co-tethered with 
RNA polymerase, as shown in Figures 3.2, 3.3 and 3.4. We demonstrated in Chapter 2 that 
strengthening promoter binding with a pss[-5] construct renders initiation less sensitive to salt. 
Adding this condition to tethered transcription should further reduce the salt sensitivity of co-
tethered complexes, increasing the desired product formation. 
As we noted in Chapter 2, using pss[-5] template DNA results in an overall decrease in 3’ 
self-extended RNA formation, even at high salt, due to the high affinity of polymerase to this 
promoter. This is due to the fact that pss[-5] lacks sequence in melting region in the nontemplate 
strand. As a result, polymerase does not exert some of its duplex promoter binding energy to melt 
open the AT rich melting region. Since the off rate is reduced, while on rate stays the same, there 
is a reduction in Kd, resulting in increased binding affinity. Since the longer impurities are never 
formed, as a result of 3’ self-extension of encoded RNA, this also results in the overall increase of 
the desired RNA products using pss[-5], and yield of encoded RNA increases even further at 
increased salt concentrations. 
We next tested the tethered system using pss[-5] similarly as we did in Figure 3.3 with the 
hypothesis that encoded RNA-24 yield would increase. Untethered transcription behaves identical 
as previously observed in Chapter 2. Detailed inspection of the tethered transcription profiles in 
Figure 3.9 reveals that at low added salt, not all cis primed extension activity is prevented using 
pss[-5], as extended products are observed, although not substantially. As expected, increasing the 
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added salt concentration further prevents nucleotide addition at the 3’ end of RNA. This shows the 
tethered system to work as expected with pss[-5] under low and high added salt concentrations. 
 
Figure 3.9. pss[-5] promoter DNA at high salt generates more yield when used in tethered 
system. A. Salt dependence of transcription profiles using pss[-5] for untethered and tethered 
complexes analyzed by 20% acrylamide, 7M urea denaturing gel electrophoresis, labeled via 
incorporation of [α-32P]ATP. The final concentrations of NaCl added to the standard reaction 
mixture are shown. 
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3.3.7. The system is stable and reusable 
In this system, Strep-T7 RNA polymerase and promoter nontemplate DNA are 
immobilized on Strep-Tactin®XT magnetic beads. This allows that this bead-immobilized 
transcription complex could be re-utilized for multiple rounds of transcription. To test this, we 
carried out three rounds of transcription using the above bead tethered transcription complex, as 
described in further detail in the Methods section, and illustrated as a scheme in Figure 3.10A. 
Results in Figure 3.10B show that there is a significant loss in overall transcription after each 
round. We hypothesized that this could be due to washing off of the template DNA with each 
round, as template DNA is only bound to the tethered system via the strong promoter contacts. 
Although promoter binding is tight, off rates of the enzyme are fast (90–92). This suggests that 
with each round of transcription, it is not unreasonable to expect some template DNA to wash off 
of the tethered system if promoter contacts are lost during the off states.  
With the observation that there is significant loss in overall transcription at each round, we 
hypothesized that strengthening promoter contacts might allow greater persistence of the complex 
on washing. In the two domain model of the 17-base pair consensus T7 promoter, the duplex 
recognition element (responsible for binding) stretches from position -17 upstream to position -5, 
while the AT rich melting region (required for optimal catalysis) is situated between positions -4 
and -1 (71). Part of the binding energy from the strong duplex binding interactions upstream of 
(and including) position -5 is used to institute conformational change in the downstream DNA, 
essentially predicted to melt bases from position -4 to about +3 (70, 93). As a result, the enzyme 
binds a partially single stranded promoter DNA that has no bases downstream of position -5 in the 
nontemplate strand (referred to here as pss[-5]) at least four times tighter than it binds double 
stranded (or pss[+2], as used here) promoter (70, 93). With significantly slower off rates (90–92) 
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and strengthened promoter binding, use of the pss[-5] promoter in the tethered system should 
reduce loss by washing and result in greater overall retention of transcription activity after each 
round of transcription.  
 
Figure 3.10. The tethered system can be reused. A) Reusability experimental order scheme. 
After 2 h of “Use 1,” the reaction solution was removed, and a new substrate NTP solution was 
added to initiate a 2 hr “Use 2” reaction (and repeated to initiate a 2 hr “Use 3” reaction). B) 
Fifteen percent polyacrylamide denaturing urea gel stained with SYBR Gold Nucleic Acid Gel 
Stain. Transcription profiles at low (0 M) and high (0.4 M) added NaCl for tethered transcription 
of RNA-24 using pss[+2], analyzed as in Figure 2. C) Fifteen percent polyacrylamide denaturing 
urea gel, stained with SYBR Gold Nucleic Acid Gel stain. Transcription profiles at low (0 M) 
and high (0.4 M) added NaCl for tethered transcription of RNA-24 using pss[-5].  
Comparison of the results in Figure 3.10C with those in Figure 3.10B confirms that use of 
the pss[-5] construct significantly increases the reusability of the tethered system, at both low and 
high salt concentrations. The gel analysis compares the products from each reaction cycle, using 
the template encoding RNA-24, under both low (0 M) and high (0.4 M) added salt conditions, and 
nontemplate DNA pss[+2] and pss[-5] respectively. The overall transcription yield decreases with 
each cycle using pss[+2], and is nearly lost by round 3. In contrast, using pss[-5] DNA, the overall 
transcription yield at each added salt concentration remains reasonably constant through three 
rounds of washing and reuse. The system can be used at least three times (more rounds were not 
tested), with essentially no loss in yield, by simply removing the product and adding transcription 
buffer with fresh NTPs.  
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Transcription in vitro by T7 RNA polymerase is a long-established method to synthesize 
RNAs of diverse lengths and sequences, due to the promoter specificity and robust nature of this 
system(20). Over the past 30 years, researchers have noted non-promoter driven activities of this 
enzyme that contaminate the product pool with other than encoded RNA products, often termed 
incorrectly as non-templated additions (20, 38–40). The quest for high yield RNA synthesis only 
exacerbates the production of undesired, longer products (32) As high concentrations of encoded 
RNA accumulate, T7 RNA polymerase binds RNA at its 3’ end and self-extends via cis primed 
extension, now independent of the promoter.  
High yield RNA synthesis efforts to date have focused on a two-step approach: 1) high 
yield transcription using T7 RNA polymerase, followed by 2) (sometimes extensive) purification 
of the encoded RNA using gel or chromatic purification methods. High yield conditions drive 
primer extension, resulting in the correct length RNA product to get converted into heterogeneous, 
longer than desired double stranded RNA contaminants. The very nature of high yield reactions 
leads directly to longer, double stranded impurities and reduces the encoded RNA yield. This 
process is sequence dependent, and in cases where the encoded RNA product does not significantly 
participate in cis primed self-extension, gel electrophoretic or chromatographic purification 
methods may be adequate to address the purity problem. However, each purification step generally 
reduces overall product yield. Moreover, electrophoretic or chromatographic purification 
approaches have highest success for relatively short RNAs. Preparative purification of longer RNA 
(e.g., separating an encoded 300 base RNA from products extended by 20-30 bases) is often 
difficult, if not impossible. With increased emphasis on mRNAs many kilobases in length, the 
problem becomes increasingly difficult.  
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The goal then is to prevent the rebinding of the synthesized RNA from the outset, to then 
prevent the RNA-primed self-extension that leads to longer impurities. Noting that high ionic 
strength inhibits all polymerase-nucleic acid interactions, we introduce here a novel in vitro 
transcription method, transcribing at high salt to limit RNA product rebinding. To restore promoter 
binding and initiation of transcription we co-tether promoter DNA and T7 RNA polymerase to 
beads. Specifically, we co-tether Strep-T7 RNA polymerase and biotinylated promoter DNA to 
Strep-Tactin®XT beads, bringing the enzyme in close proximity to its promoter to restore promoter 
binding, even at high ionic strength. This results in overall higher yields of the desired RNA at 
greater initial purity, reducing the need for subsequent (and low yield) purification steps.  
3.4.1 Tethering plus salt leads to improved transcription purity and yield.  
Increasing salt concentrations leads to complete inhibition of all enzymatic activity in the 
untethered system, as shown in Figures 3.3, 3.4 and 3.5. In the tethered system, high salt inhibits 
only the undesired cis-primed extension activity of T7 RNA polymerase, while allowing promoter-
directed transcription. This reflects as a dramatic decrease of the longer, double stranded 
impurities. Since production of the longer double stranded products derives from and therefore 
consumes encoded-length RNAs, tethered system recovers higher yields of the desired (directly 
encoded) product. As expected, at sufficiently high concentrations of added salt, promoter driven 
transcription begins to be inhibited, even for the tethered system. For these constructs and these 
conditions, a practical optimum of about 0.3 M added NaCl provides a good trade off of purity vs 
yield. While these experiments have been carried out on relatively short RNAs, the almost identical 
behavior of 24 and 34 length encoded transcripts argues that this result should be generalizable to 
any length RNA (e.g., mRNA and lncRNA).  
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3.4.2 Bead co-localization renders transcription resistant to salt  
To characterize the salt dependence of promoter-driven transcription in the (relative) 
absence of primer extension, we used a sequence, RNA-24Alt, previously observed to yield less 
of the resolvable primer extended products(32). The results in Figure 3.4 show that while in the 
untethered system, overall transcription is inhibited progressively with increasing added NaCl, the 
tethered system continues to generate high yields of RNA-24Alt at moderate salt concentrations. 
Note that at 0.1 M added NaCl, encoded RNA yield increases somewhat for both untethered and 
tethered transcription systems, when compared to 0 M added NaCl. As discussed earlier, this 
observation suggests that this RNA sequence is in fact subject to primer extension, but to a lower 
extent and in a more dispersed heterogeneous (and therefore less readily visualized in a gel) 
manner. Thus, even in an untethered system, low salt concentrations may reduce primer extension 
with limited effect on promoter binding and initiation. 
As the titration approaches 0.3 M added NaCl, the tethered system reaches maximal yield 
of encoded length RNA, while the untethered system is inhibited significantly. At 0.4 M added 
NaCl, the overall yield in the tethered system starts to drop, as the effect of high salt on inhibiting 
even promoter-driven transcription becomes significant. This behavior parallels the results 
observed for RNA-24 in Figure 3.3. For practical consideration, users can determine the optimal 
concentration of added salt, depending on their RNA sequence, targeted degree of purity, and 
desired yield.   
3.4.3 Generality of the system 
The characterization experiments shown in Figures 3.3 and 3.4 have been carried out on 
relatively short RNAs 24 bases in length. To test the generality of the system, we used a DNA that 
encodes a 34 base RNA (RNA-34) and carried out transcription using the tethered system. The 
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results in Figure 3.5 exhibited similar characteristics in terms of transcription profile, salt 
sensitivity and overall transcription yield. The similarity in transcription trends in 24 base and 34 
base encoding tethered systems suggest these characteristics to be generalizable for other RNA as 
well. The synthesis here of relatively short 24 and 34 base RNAs, allows precise analytical 
characterization of both yield and impurities, but since conversion to a fully stable elongation 
complex is complete by about 9-10 bases, we fully anticipate that this system can be extended to 
much longer RNAs. Thus, this system should be readily used in the synthesis of CRISPR guide 
RNAs, long noncoding RNAs, and mRNA. 
3.4.4 Stability of the system 
In RNA therapeutics applications, high yields of pure RNA are needed for research and 
drug production purposes. In order to achieve high yields, researchers routinely carry out in vitro 
transcription using T7 RNA polymerase for long hours under high RNA generating conditions(20, 
23, 67, 94). Production under those conditions results in the generation of longer, double-stranded 
impurities, which then requires extensive purification to recover only the encoded RNA(61–63, 
95–97). At long RNA lengths, purification methods do not have the resolution to eliminate all 
impurities (for example, separating a 2,000 base transcript from a 2,040 base impurity) and 
purifications lead to a loss in yield. Moreover, since longer, double-stranded impurities are 
generated via the extension of correct length, encoded RNA, the synthesis itself leads to a loss in 
yield of the intended length product. The approach outlined here improves yield in both respects.  
As the needed overall yield increases, as in therapeutic production, economic 
considerations play a significant role in the design of synthesis approaches. Earlier studies have 
described approaches to reuse DNA in transcription reactions. In one such approach, Davis and 
colleagues tethered synthetic DNA to a solid surface and claimed 15 rounds of transcription using 
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the same DNA, with the ability to store the system between rounds(58). In that system, however, 
RNA polymerase must be added at each round; but more importantly, the polymerase is un-
tethered and, as in solution reactions, as RNA product accumulates, primer extension will occur, 
lowering purity and target RNA yield. Thus, while template DNA is reused, that approach is not 
expected to improve the profile of the RNA generated in high yields.  
 The system described here is fundamentally different, in that it tethers both promoter DNA 
and T7 RNA polymerase, in proximity, to magnetic beads and carries out transcription at high salt, 
so that cis-primed extension activities are inhibited, resulting in an increase in overall yield and 
purity of the encoded RNA. To further improve the yield of this system, we reused the beads for 
multiple rounds of transcription, using the same DNA and enzyme, but additionally strengthening 
promoter binding by use of a partially single stranded promoter construct. Comparing the results 
in Figures 3.10B and 3.10C, strengthening promoter contacts using pss[-5] indeed helps retain 
template DNA during washing and allows at least 3 repetitions of 2 hour reactions. When 
compared with the routine (untethered) transcription reaction profile seen in Figure 3.3A, the 
overall transcription yield of the encoded RNA is improved dramatically. This new system offers 
dramatic improvements in encoded RNA yield and purity. 
3.5 SUMMARY 
In summary, the approach described here yields substantial improvements in RNA 
synthesis compared with the typical approaches of the past. We demonstrate a novel approach to 
in vitro transcription that prevents formation of longer than encoded, double stranded impurities 
observed in high yield transcription reactions. With this system, T7 RNA polymerase activity is 
exclusively promoter specific, with the inhibition of non-promoter specific activity (including 
RNA self-primed extension). The near elimination of primer extended products that typically occur 
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in high yield transcription reactions improves purity dramatically, while eliminating the extension 
of correct length RNA increases the overall yield of the desired RNA product. This approach 
further allows easy separation of product from RNA polymerase and from the templating DNA, 






















Table A2.  DNA sequences and constructs used in Chapter 3 
 
 





























































NOVEL METHODS FOR THE AFFINITY PURIFICATION OF ENCODED RNA 
 
4.1 INTRODUCTION 
T7 RNA polymerase transcription in vitro is a well-established enzymatic synthesis method 
to efficiently produce high yields of RNA longer than 20-50 nt (20, 23, 66, 67). However, as noted 
in Chapter 1, the purity is often not good, as polymerase participates in non-promoter specific 
activity that leads to size and sequence heterogeneity at the 3’ ends (30).  In addition, polymerase 
can produce short RNAs of 2-9 nt long via abortive cycling (20, 37, 98). Furthermore, DNAs used 
in these transcription reactions may get degraded during storage and use, and such shorter 
templates may encode RNAs shorter than desired length.  
Purification of enzymatically synthesized 
RNA is routinely done by gel or chromatographic 
purification methods that have been around for 
the past 30+ years (63, 96). These methods are 
arduous, time consuming and often result in a 
massive loss in yield. In addition, we recently showed through RNA-seq data that the most 
abundant product is often not the correct one, such that purifications that focus on the most 
abundant product may be purifying the wrong product (32)! In addition, gel analyses are prone to 
showing a product pool that “looks” pure to the naïve eye, even if the sample contains relatively 
large amounts of widely dispersed shorter and longer impurities. For mRNA used in RNA 
therapeutics research, impurities in in vitro T7 RNA polymerase generated mRNA have been 
reported to induce an unintended immune response and may have potentially fatal results if 
administered in therapies (69).  
Common impurities in RNA synthesis 
• Abortive RNAs (2-15 bases) 
• Less than full length RNAs (n-i) 
o From internal termination 
o From degraded DNA templates 
• 3’ double stranded extensions (n+i) 
o From (self) cis-priming 




Here, we develop a simple affinity purification method using capture DNA immobilized 
on magnetic beads to purify high yields of encoded RNA, as shown in Figure 4.1. In this use, the 
capture DNA has sequence complementarity to the 3’ end of the encoded RNA and is immobilized 
on beads via covalent linkage or the strong streptavidin-biotin interaction. This method allows the 
purification of only encoded RNA (n) by capturing it on magnetic beads, while washing away the 
other RNAs (abortives, truncated RNAs, primer extended RNAs) and transcription reagents 
(promoter DNA, polymerase, NTPs, Mg(II), pyrophosphatase, RNAse inhibitor murine) in one 
simple step.  
 
Figure 4.1. Design of an affinity capture RNA purification method. Bead immobilized capture 
DNA as an affinity tag purifies only the desired RNA, while all other RNA products and 
transcription reagents and are washed away. 
4.2 MATERIALS AND METHODS 
4.2.1. Reagents  
DNA oligonucleotides used in transcription reactions were purchased from Integrated 
DNA Technologies (IDT). DNA and RNA sequences and constructs used in this chapter are shown 
in Table A3. The following buffers were optimized in house and used where indicated.  
High yield transcription buffer contained 30 mM HEPES, 40 mM magnesium acetate, 25 
mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8, 10 units/ml pyrophosphatase 





































1 mM EDTA. Low yield transcription buffer contained 30 mM HEPES, 15 mM magnesium 
acetate, 25 mM potassium glutamate, 0.25 mM EDTA, 0.05% Tween20, pH 7.8. Elution buffer 
contained 10 mM Tris-HCl (pH 7.5), 1 mM EDTA.  
4.2.2. T7 RNA polymerase 
His tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying 
the plasmid pBH161; purified and characterized as previously described (29).  
4.2.3. Transcription reactions 
All reactions were performed using partially single-stranded DNA constructs, in which the 
nontemplate DNA oligonucleotide extends downstream only to position +2 (NT+2), unless noted 
otherwise. All ‘high yield’ transcription reactions were carried out in the presence of 2 μM each 
of nontemplate and template DNA oligonucleotides, 7.5 mM of each NTP, and 1.5 μl T7 RNA 
polymerase Mix™ (New England Biolabs) in an overall 20 μl reaction volume at 37°C for 4 h 
(unless noted otherwise in the manuscript). High yield transcription reactions in the presence of 
capture DNA additionally contained 400 μM (unless noted otherwise) capture DNA.  
4.2.4. DNAse I reactions 
All DNAse I (New England Biolabs) reactions were performed according to protocol 
provided by NEB.  
4.2.5. RNA self-primed extension reactions 
Reactions with synthetic RNA, in the absence of promoter DNA, were conducted with 25 
μM synthetic RNA in the presence of 0.5 μM T7 RNA polymerase and 0.4 mM each of guanosine 
triphosphate, cytidine triphosphate, adenosine triphosphate (ATP) and uridine triphosphate. 
Reactions were carried out at 37°C for 5 min in low yield transcription buffer. For self-primed 
extension reactions in the presence of dual capture DNA, or both dual capture DNA and universal 
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sequence, DNA oligonucleotides, dual capture DNA contained 3′ amino modification and one or 
both oligos were added to reaction mixtures to a final concentration of 25 μM. 
4.2.6. Gel electrophoretic analyses 
Reaction products were analyzed with 20% polyacrylamide, denaturing (7 M urea) gel 
electrophoresis. For Figures 4.3, 4.4, 4.16, transcribed RNAs were labeled by including [α-32P] 
ATP (PerkinElmer) in the reaction mixture (without reducing the concentration of ATP). For all 
other figures, RNAs were visualized by SYBR™ Green II RNA Gel Stain (Invitrogen).  
4.2.7. Bead binding and elution experiments  
Magnetic bead experiments were carried out using Oligo d(T)25 Magnetic Beads, 
Streptavidin Magnetic Beads (both NEB) and Strep-Tactin®XT beads (IBA Lifesciences), as 
indicated.  
4.2.8. Other reagents  
T4 DNA polymerase, Phi29 DNA polymerase and DraI were purchased from New England 
Biolabs and their respective protocols were adapted from their provided datasheets. CircLigaseTM 
was purchased from Lucigen and used according to the provided data sheet. DNA ladder was 
purchased from IDT and they mark 100 nt through 20 nt in length at 10 nt intervals. 
4.3 RESULTS  
4.3.1. Capture purification post synthesis 
In order to test that bead immobilized capture DNA can affinity purify only encoded RNA 
from a pool of RNA products, we used a streptavidin magnetic bead to immobilize a 5’ biotinylated 
capture DNA on, as shown in Figure 4.2A, where capture DNA had sequence 17 nt 
complementarity to the 3’ end of RNA-24. We chose a BioTEG functionality that has a TEG 
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(triethylene glycol) linker to limit steric hindrance for efficient DNA binding and RNA capture 
and added amino modification at the 3’ end to prevent undesired extension by polymerase. This 
capture DNA is called Capture DNA-24. We carried out transcription for RNA-24, a 24 base RNA 
known to participate substantially in cis self-primed extension, as shown in Figure 4.2B, 
transcription pool. In high yield transcription reactions, 3’ primed self-extension from this RNA is 
significant; almost all the encoded RNA-24 extended to longer, double stranded impurities. In 
order to have a heterogeneous RNA pool including RNA-24 and longer impurities, we therefore 
carried out transcription under low yield conditions. After transcription, we incubated the 
transcription product pool with magnetic bead-immobilized capture DNA, as shown in Figure 
4.2A. We hypothesized that from a pool of heterogeneous RNA, only the desired RNA (RNA-24) 
would bind to streptavidin magnetic beads, while transcription byproducts like longer double 
stranded RNA, intermediate length RNA, and abortive RNA would come away in the bead wash.  
Figure 4.2A shows the hypothesized scenario, where RNA-24 is captured by bead immobilized 
capture DNA, whereas other products and reagents are washed away in solution. In Figure 4.2B, 
the heterogeneous transcription pool is shown in lane 1 as “Transcription Pool”, where RNA-24, 
and longer impurities are abundant, as expected. After incubating the transcription pool with the 
bead immobilized Capture DNA-24, the bead supernatant was removed, as shown in Figure 4.2B, 
“Unbound”. Next, beads were washed once with wash buffer, as shown in Figure 4.2B, “Wash”. 
Lastly, beads were resuspended in wash buffer to visualize all RNA that was “Bound” on the 
beads.  As expected, while longer, partially double stranded RNA impurities are washed away in 
the supernatant (“Unbound”), only encoded RNA is captured via the Capture DNA-24 
immobilized on streptavidin magnetic beads (“Bound”). There is a small leakage of RNA-24 in 
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the washing step (“Wash”), as the bead capacity may be too small to be able to bind all the RNA-
24 generated in this transcription reaction, but the majority remains bound to the beads.   
 
Figure 4.2. Purification of RNA-24 post transcription using capture DNA immobilized 
streptavidin beads. A. Scheme of streptavidin magnetic bead tethered capture DNA collecting 
desired RNA post transcription. Capture DNA with a 5’ biotin tag and TEG linker has sequence 
complementarity to 3’ end of RNAn and is bound to streptavidin magnetic beads.  B. Low yield 
transcription of RNA-24 shown as “Transcription Pool”; supernatant washed shown as 
“Unbound”, second wash shown as “Wash”; bead captured RNA-24 and capture DNA affinity 
tag shown as “Bound”. 
4.3.2. Capture during synthesis 
While this approach can specifically purify full length RNA from a reaction, it does not 
prevent the wasteful conversion of correct length RNA to longer, double stranded product during 
transcription. We have recently demonstrated that addition of a similar capture DNA to the 
transcription reaction sequesters the 3’ end of the (encoded) RNA to prevent primer extension (47). 
It seemed reasonable then to couple that approach with the current approach. In this case, the 
capture DNA would be biotinylated, and pulled away after transcription with streptavidin beads. 
Figure 4.3 shows in the absence of capture DNA during transcription, RNA-24 and longer 
impurities are formed at high yields, as expected. When transcription is carried out in presence of 
biotinylated capture DNA-24, formation of longer impurities is prevented. After transcription, the 





































and the beads were then washed. As above, the correct RNA-24 product is bound on the beads, 
and recovered, while what was not bound was washed away.  
 
Figure 4.3. Capture & purification of RNA-24 during transcription using capture DNA-24 beads 
Transcription in presence and absence of capture DNA (Transcription, -, + capture) and the 
purification of encoded RNA-24 (and intermediates) from the transcription pool after 
incubating with streptavidin magnetic beads. RNA-24 bound to the beads shown as “Bound”; 




































Note in Figure 4.3 that intermediate length (n-i), but not short abortive, products are co-
purifying with the correct length products (it is thought that these products arise from failure to 
fully complete the transition from initiation to elongation). Since the full-length product in this 
experiment is only 24 bases in length, and the capture DNA-24 is complementary to the 3’ terminal 
17 bases of the encoded RNA, an encoded 15mer, for example, would have 8 bases of 
complementarity with the capture DNA. It appears that under these conditions, this may be 
sufficient for at least some functional capture affinity. This suggests that for longer RNAs, while 
these 12-15mer products will not co-purify, products several bases short of full length may. In 
cases where slightly shorter than full length RNAs are problematic, users may need to 
experimentally titrate the length of the capture DNA to optimize capture of full-length RNA, while 
not capturing shorter products. 
4.3.3. Generality of the approaches  
The above experiments were carried out with a very short RNA sequence. In order to test 
the method for RNA of varying lengths and sequences, we repeated the experiments of Figure 4.3 
on a DNA template (DNA-34Alt) encoding RNA-34Alt. This sequence participates in 3’ self-
extension activity much less than RNA-24. The encoded RNA is 34 nt long, and the sequence 
specific affinity tag is the same length as in Figure 4.3, but different in sequence to capture this 
sequence RNA at its 3’ end. The results presented in Figure 4.4 demonstrate that in the absence of 
capture DNA-34Alt, two distinct bands around 34 nt are observed. We hypothesized these are n 
and n+1 or n+2 products due to their close proximity in gel migration. There are also some 
extended products, but at a population significantly less when compared with the results in Figure 
4.3, since this RNA-34Alt participates in 3’ self-extension activity much less than RNA-24. Upon 
addition of the capture DNA-34Alt in the transcription mix, as nascent RNA-34Alt binds the 
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capture DNA-34Alt at its 3’ end, the small amount of cis primed extension activity that occurs for 
this template is inhibited.  
 
Figure 4.4. Capture DNA Purification of RNA-34Alt. Transcription in presence and absence of 
capture DNA-34Alt (Transcription, -, + capture). Purification of encoded RNA-34Alt (and 
intermediates) with streptavidin tethered capture DNA-34Alt. RNA-34Alt is bound to the beads 






























Note that the relative absence of longer primer extended products from this template allows 
resolution of n+1 and n+2 products migrating just above the expected band. The results in Figure 
4.4 show a substantial reduction in n+i product, as expected if these arise from the same primer 
extension mechanism. Upon incubation with the streptavidin beads, only correct RNA-34 product 
is purified away from the transcription mixture (lane 3), and the rest is washed away with the 
supernatant. However, the same problem observed with the unintended purification of 12-15mer 
intermediate products are also observed here. Future studies will characterize this more fully, 
including the screening of buffers, temperature, and capture sequence length for more stringency 
in binding. 
4.3.4. Increasing the capacity of the system 
While streptavidin beads served well in demonstrating proof of concept for our affinity tag 
purification system demonstrated in Figure 4.1, the yield of RNA is limited stoichiometrically by 
the biotinylated DNA binding capacity of the streptavidin magnetic beads. 
It is reported these streptavidin magnetic beads have capacity for binding 500 pmol single 
stranded 25 bp biotinylated oligonucleotide per mg of beads. In order to efficiently capture & 
purify encoded RNA during transcription 400 µM capture DNA was reported as minimum 
required amount for a 20 µL high yield transcription reaction (47). This means 16 mg of beads 
would be required to purify only one transcription reaction efficiently. This is not cost-friendly, 
and experimentally complex, as 16 mg of beads are physically near impossible to separate 
magnetically from a 20 µL solution. While these beads are efficient for quick and small-scale 
purification of RNA, they are not efficient in purifying high yields of RNA. 
In order to overcome the capacity issue observed with streptavidin magnetic beads, we 
used an alternative bead covalently coated with Strep-Tactin®XT. Strep-Tactin®XT is a 
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specifically engineered variant of streptavidin and biotin is reported to have picomolar binding 
affinity to Strep-Tactin®XT. In addition, Strep-Tactin®XT coated magnetic beads have very high 
capacity: Strep-tag® II fusion proteins are reported to have 0.085 nmol/µL capacity beads (e.g. 
25.5 ug of a 30 kDA protein). Since there were no reported number for DNA binding capacity, we 
took this number as a ballpark estimate and tested for our own purposes in house.  
 
Figure 4.5. Capture DNA binding capacity of Strep-Tactin®XT beads. 200 pmol, 400 pmol, 800 
pmol and 1.6 nmol capture DNA were bound on 2 µL Strep-Tactin®XT beads and supernatants 
washed. “All” lanes represent all capture DNA before incubating with the beads, “Unbound” 
lanes represent what washed away, and “Bound” lanes represent capture DNA bound on 
beads.  
We tested the capacity by binding increasing amounts of biotinylated capture DNA-24 (0.2, 
0.4, 0.8, 1.6 nmol) to 2 µL Strep-Tactin®XT dry beads. Figure 4.5 shows that 2 µL dry beads has 
the capacity to bind at least 1.6 nmol capture DNA-24. Previously published work demonstrated 
that in order to inhibit the cis primed extension polymerase activity in high yield transcription 
reactions, there needs to be 400 µM of capture DNA in a high yield transcription reaction mix to 
bind the appropriate product RNA (47). This would translate to 4 nmol of capture DNA in a 10 µL 
transcription reaction, meaning one would need to incubate 5 µL beads with 4nmol capture DNA 
to prevent such extension activity. This is a reasonable amount of bead in a 10 µL solution, 
especially when compared with the requirement of streptavidin beads  
































Figure 4.6. Synthetic RNA-24 binding and elution on high capacity Strep-Tactin®XT beads.  
Binding of synthetic RNA-24 on Strep-Tactin®XT bead immobilized capture DNA and its 
subsequent elution by heating the complex to 40 °C	for	2	min. 
Having confirmed that these beads have substantially larger capacity than streptavidin 
beads, at amounts sufficient to inhibit cis primed extension activity of T7 RNA polymerase, we 
tested their RNA binding capacity. We incubated equal amounts of synthetic RNA-24 with Strep-
Tactin®XT immobilized capture DNA-24. We bound 1.6 nmol RNA to Strep-Tactin®XT 
immobilized 1.6 nmol capture DNA-24 by incubating them in wash buffer for 45 min in room 
temperature. After, we separated the supernatants from the beads and collected for analysis, shown 
as “Unbound” in Figure 4.6. Since there was no RNA in this lane, we concluded all RNA was 
bound on capture beads. Next, we wanted to elute the RNA-24 from the beads using heat. Rough 
predictions suggested a Tm of about 38 °C for the RNA:DNA hybrid. Therefore, we eluted RNA-
24 from the bead-bound capture DNA-24 by renaturing beads in elution buffer and heating to 40 
°C for 2 min. However, elution of RNA-24 was only partial under these conditions. Most of the 
RNA-24 stayed on the bead tethered capture DNA. This suggests that the elution step needs to be 



























4.3.5. Rolling Circle Amplification as a tool to improve binding sites per oligo bound 
on beads 
We hypothesized that if the oligo DNA binding capacity of non-porous bead systems are 
too small to purify large quantities of product RNA from high yield transcription reactions, and if 
the porosity of high-capacity beads may hinder the binding of long RNAs (such as mRNA), we 
needed to invent a novel method to increase the RNA binding sites per capture DNA oligo bound 
on beads. In order to improve the capacity of any bead, I invented a novel approach utilizing rolling 
circle amplification to amplify binding sites available per oligo bound on beads.  
Figure 4.7 demonstrates the design of a novel method developed to amplify binding sites 
per oligo bound on beads. First, a 5’ phosphorylated template DNA is circularized using via direct 
or splint ligation. Then, the circularized template DNA encoding the capture DNA sequence is 
hybridized to an RCA primer DNA oligo that will be extended from its 3’ end. Phi29 polymerase 
initiates rolling circle amplification from this primer, using circular DNA as a template to generate 
a long linear DNA with repeated sequences of Capture DNA, as shown in Figure 4.7A. A starting 
RCA primer is amplified to a long DNA with many capture DNA sites, so that high yields of 
desired RNA can be bound for purification, as shown in Figure 4.7B. Figure 4.7C demonstrates 
different strategies used in this work to immobilize the RCA primer (or the amplified RCA primer) 
on solid support (magnetic beads).  We hypothesized that the RCA primer could either be bound 
on beads first, to allow for RCA reaction to take place on the beads, or the RCA reaction could be 





Figure 4.7. Design of a novel method to improve capacity per oligo bound on beads. A. Rolling 
circle amplification mechanism of capture DNA sequence that improves on binding sites per 
starting capture DNA oligo. B. Rolling circle amplified capture DNA sequence binds high yields of 
desired RNA. C. RCA primers selected to bind different magnetic beads via covalent linkage and 
streptavidin-biotin interaction  
4.3.6. Rolling circle amplification of capture DNA sequence in solution  
We first circularized a 5’ phosphorylated RCA Template 1 (68 nt), that had of 4 repeats of 
the previously used 17 nt capture-DNA sequence using CircLigase®, as shown in Figure 4.8 and 
4.9A. After successful circularization, we hybridized the circular RCA Template 1 with RCA 




































reaction using Phi29 DNA polymerase for 1 h and 16 h. We also performed the same reaction 
using Linear RCA Template 1 and RCA Primer 1.  While the Linear Template 1 did not perform 
rolling circle amplification, as expected, both 1h and 16 h RCA reactions using the Circular RCA 
Template 1 had gooey consistency, indicating efficient amplification and gelation of the long 
DNA. To further confirm the amplification, we stained the reactions with Sybr Green dye, as 
shown in Figure 4.9B. Both 1h and 16h reactions using the Circular RCA Template 1 were stained 




Figure 4.8. Scheme of Rolling Circle Amplification of Capture DNA sequence and subsequent 
immobilization on streptavidin magnetic beads. 5’ phosphorylated Linear Template 1 is 
circularized using CircLigase®, bound with RCA Primer 1 and rolling circle amplified using Phi29 
DNA polymerase. Amplified capture DNA is bound to streptavidin magnetic beads using 
streptavidin-biotin interaction. High yields of encoded RNA is bound on the repeated capture 















Next, we tested if RNA-24 could successfully bind to this amplified capture DNA oligo. 
In order to do this, we incubated the both 1 h and 16 h amplified capture DNA products with 8 µM 
synthetic RNA-24. After hybridization, we performed brief RNAse H digestion for 30 min at 37 
°C on these samples as shown in Figure 4.9C. As a negative control, we performed RNAse H 
digestion on same amount of single stranded RNA-24 in solution, which showed no substantial 
decrease in intensity, demonstrating that RNAse H indeed cannot digest free RNA in solution. We 
then tested, as a positive control, digestion of 8 µM synthetic RNA-24when in complex with 20 
µM DNA oligo that had the 17 nt capture DNA sequence (T-24). Results showed cleavage of 
RNA-24, while the DNA intensity remained unchanged, as expected. Therefore, we confirmed 
RNAse H cleaves RNAs in a RNA:DNA hybrid. Lastly, when 1 h and 16 h amplified DNA was 
incubated with synthetic RNA, in presence of RNAse H, the nuclease cleaved all RNA in an 
RNA:DNA hybrid, as shown in Figure 4.9C .  Results shown in Figure 4.9C demonstrate 
successful binding of RNA-24 on RCA amplified RNA primer. 
4.3.7. Binding the amplified capture DNA to streptavidin beads 
Next, we incubated the RCA amplified capture DNA on streptavidin beads using the 5’ 
biotin tag and follow up with RNA incubation. We hypothesized that amplified, 5’ biotinylated 
capture DNA will bind to the beads, and upon incubation with RNA-24, we will capture the 
synthetic RNA in beads. However, results in 4.9D show that binding of this long RCA product to 
NEB Streptavidin beads was not achieved, as all RNA-24 was washed away to solution, and not 
bound on the beads. We treated the bead complex with DNAse I for 30 min at 37 °C to test if the 
RNA was not denatured off from the beads. However, this did not show RNA bound on the beads 
as well. Therefore, we hypothesized that the long and entangled DNA hid the biotinylated 5’ end 
in its core.  
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As an alternative approach, we tried to perform rolling circle amplification reaction on the 
RCA primer after tethering the primer on the streptavidin beads. However, we were not able to 
accomplish RCA on bead tethered primers (results not shown). We hypothesized that there was 
steric hinderance on the bead tethered RCA primer, preventing Phi29 polymerase from efficient 
amplification. It was evident that we needed to first optimize the RCA for amplified DNA length 
so that it won’t end up tangling or turn into gel form. 
 
 
Figure 4.9. Circularization and rolling Circle Amplification of Capture DNA, followed by its 
subsequent binding to RNA-24 A. Circularization of RCA Template 1 using CircLigaseTM and its 
follow-up exonuclease treatment B. Rolling circle amplification of negative controls and circular 
RCA template 1, stained with Sybr Green II C. Binding of RNA-24 to rolling circle amplified 
capture DNA and RNAse H assay of RNA:DNA hybrids  D. Binding of rolling circle amplified 
capture DNA to streptavidin magnetic beads.  
4.3.8. Binding to dT(25) beads 
As an alternative to immobilization by protein affinity we have also explored 
immobilization using Oligo dT(25) beads, from New England Biolabs. These beads are routinely 
used for small scale purification of mRNA from cell lysates and tissue via affinity to cellular 
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dT25 allows us to use the T25 oligo as an RCA primer, and extend it from its 3’ end using an RCA 
template containing A25, as shown in Figure 4.10. 
 
 
Figure 4.10. Scheme of Rolling Circle Amplification of Capture DNA sequence and subsequent 
immobilization on dT(25) magnetic beads. 5’ phosphorylated Linear Template 2 is circularized 
and rolling circle amplified using Phi29 DNA polymerase on T25 primer covalently tethered on 
beads. Amplified capture DNA is digested using Dra1 for analysis.  
In order to do this, we circularized RCA Template 2 DNA using either Circligase® or T4 
DNA ligase, as shown in Figures 4.11A and 4.11B, respectively. We followed circularization with 
Exo I and III digestion to get rid of any linear DNA left in solution. We observed multiple bands 
of circularized DNA, suggesting different lengths of circular DNA formation as a result of linear 










3. Dra1 Digestion 
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Figure 4.11. Circularization of Linear RCA Template 2 using direct and splint ligation 
techniques. A. Circularization of Circular CTRL template (provided by IBA Lifesciences as a 
positive control) and Linear RCA Template 2, and their exonuclease digestion to digest non-
circularized templates B. Circularization of Linear RCA Template 2 using T4 DNA Ligase and a 
split DNA, and their exonuclease digestion to digest non-circularized templates. 
 
Next, we hybridized a synthetic dT(25) DNA, as a mimic to the bead tethered T(25) DNA to 
the circularized templates, and performed rolling circle amplification using Phi29 DNA 
polymerase. In order to better visualize the long RCA product, instead of Sybr Green staining in 
Eppendorf tubes, we used a restriction enzyme Dra1 that can digest double stranded DNA with the 
recognition sequence TTTAAA. We included this recognition sequence in the RCA template DNA 
2, so that we could cleave it at strategic positions as shown in Figure 4.10 and visualize digested 
15 nt DNA in gel analysis. This way, we could also digest the RCA product from dT(25) oligo in 
beads for visualization as well, since covalently bound amplified DNA would not dissociate from 
bead using heat unlike the streptavidin-biotin interaction.  
Since we previously observed DNA tangling and gelation in 1 h and 16 h reactions, we set 
out to optimize the control DNA lengths by adjusting ddNTP/dNTP ratios to find the right length 
of amplified DNA. We performed RCA amplification with increasing ddNTP/dNTP ratios and 
digested the products using Dra I as shown in Figure 4.12. First, we checked DraI activity on a 






Exo I & III- -+ +
T4 DNA Ligase++















sequence of the DNA predicts that digestion of the 30 base CTRL Template 1 will lead to 15 nt 
DNA oligos. We did observe such digestion, but not at 100%, which showed that the enzymatic 
activity was not high enough to digest all the products in the RCA reaction. However, we decided 
to go forward with this method as a tool to confirm rolling circle amplification, since we only 
needed to see a trend to make an assessment of the results and would not require 100% digestion 
of the RCA product. Figure 4.12 shows that with increasing ratio of ddNTP/dNTP, there is a 
decrease in the digested product that migrates around the 25 nt length. We hypothesized this band 
to be the 15 nt band of CTRL template, so the higher migration of a digested DNA product could 
be due to incomplete denaturation in gel running conditions.  These results suggest RCA reaction 
is performing well at 1/2000, 1/1000 and 1/500 ddNTP/dNTP ratios.  
 
Figure 4.12. Controlling rolling circle amplified DNA length by increasing ddNTP/dNTP ratios 
and their analysis with restriction digest using Dra I. A control reaction using CTRL Template 1 
with TTTAAA recognition sequence demonstrates efficient Dra I digest. Increasing ddNTP/dNTP 
ratio shows decrease in the digested 25 nt product. 
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Having confirmed functional RCA in solution with new template and primer sequences 
(RCA Template 2 and RCA Primer 2), we next performed RCA on NEB Oligo d(T)25 Magnetic 
Beads, using the covalently immobilized d(T)25 as the primer. Similar to the design demonstrated 
in Figure 4.1, we hybridized the circularized RCA Template 2 with the d(T)25 oligo covalently 
tethered to magnetic beads. After hybridization, we carried out RCA reaction on beads at 
increasing ddNTP/dTP ratios of 1/5000,1/1000 and 1/250. We expected the RCA efficiency to be 
less on bead surface when compared to in solution, due to possible steric hindrance and the 
limitation of low concentration T(25) oligo bound on these beads. The exact amount covalently 
tethered on beads was not reported by NEB, but the beads are advertised for low capacity mRNA 
purification, thus we expected it to be a possible limiting factor. After the RCA reaction, we 
performed Dra 1 digestion on all samples, as before and visualized the digestion products on the 
20% acrylamide denaturing polyacrylamide gel. Control reactions in Figure 4.13 demonstrate Dra1 
to be active and able to digest the control reaction. Dra 1 digestion looks to be much less overall 
when compared with solution RCA results in Figure 4.12, which was expected. Upon Dra 1 
digestion, a new band is observed around 25 nt for RCA products from 1/1000 and 1/250 
ddNTP/dNTP ratio reactions, suggesting that amplification was successful in these samples. We 
have observed neither circular DNA, nor cut DNA for the 1/5000 lane. This is surprising, since it 
was expected to be the longest RCA product. We hypothesized that the long RCA product may 
not be denaturing to release the hybridized products into the gel front, as circular DNA and CTRL 




Figure 4.13. Rolling circle amplified DNA reactions on covalently bead immobilized T(25) DNA 
primer with increasing ddNTP/dNTP ratios and their analysis using restriction digest Dra I. A 
control reaction using CTRL Template 1 with TTTAAA recognition sequence demonstrates 
efficient Dra I digest. Increasing ddNTP/dNTP ratio shows decrease in the digested 25 nt 
product. 
Having demonstrated the rolling circle amplification reaction using dT(25) magnetic beads 
and Circular DNA Template 2, we went on to test the binding capacity of these amplified beads 
by incubating them with RNA-24 at 90 µM. We incubated RNA-24 with the beads at room 
temperature, and separated supernatants, shown as “Unbound” in Figure 4.13. We washed the 
beads with wash buffer once, shown in Figure 4.14 lane “Wash”, and resuspended in wash buffer, 
as shown in lane “Bound”. Results show that only a small fraction of 1-10 µM of RNA-24 was 
captured by dT(25) beads, while the rest washed away or was never bound. This is not sufficient in 
reducing cis primed extension activity in high yield transcription reactions, or to purify high yields 
of RNA post transcription.  Future experiments will focus on boosting rolling circle amplification 






















Figure 4.14. Binding of synthetic RNA-24 on rolling circle amplified dT(25) magnetic beads. 90 
µM of RNA-24 was incubated with rolling circle amplified dT(25) beads and unbound, washed 
and bound species were analyzed on 20% denaturing PAGE, stained with Sybr Gold. 
4.3.9. Universal Purification System     
To generalize the purification platform to be applied for any sequence of RNA, we 
developed a “next generation” design for the Capture-DNA tethered bead system. As shown in 
Figure 4.15, a “universal sequence” DNA oligo is assigned as the staple sequence that could be 
used by the system by default. Each time an RNA sequence needs to be purified; the end user 
orders a new “dual capture DNA” oligo. The dual capture DNA has a sequence complementarity 
to the universal sequence DNA on one half, and to the RNA sequence to be purified on the other. 
The universal sequence is tethered on magnetic beads for the pull-down assay. This method could 
be used during (dual capture DNA would take the role of cis primed extension inhibitor) or post 

















Figure 4.15. A universal capture DNA purification system. A. Universal sequence DNA is 
immobilized on magnetic beads by its 3’ end. Dual capture DNA then has sequence 
complementarity to both the universal sequence and to the desired RNA 3’ end. B. Universal 
sequence DNA is immobilized on magnetic beads by its 5’ end. Dual capture DNA has sequence 
complementarity to both the universal sequence and to desired RNA. To prevent primed 
extension in (A) the 3’ end of the dual capture DNA is amino-modified and in (B) the 3’ end of 
the universal sequence is amino-modified. 
If dual capture DNA is used in the role of a cis primed extension inhibitor during 
transcription, the 3’ end of the DNA would need to have an amine modification to prevent its 
undesired extension by T7 RNA polymerase (this is straightforward and inexpensive). We also 
realized that the direction of the dual capture DNA would have importance in the efficiency in 
prevention of cis primed extension reaction. Since one direction would sit blunt to the 3’ end of 
RNA, the other direction would be a template under the product RNA where 3’ end is exposed. 
Although we would expose the 3’ end RNA for nonspecific extension activity in this direction, we 
hypothesized such activity could be prevented by also adding the universal DNA in the 
transcription solution, preventing exposure of single stranded DNA to act as template for 
polymerase. Therefore, we tested two possible directions in the design of a universal system as 






























4.3.10. Free 3’ RNA.  
We first tested the model demonstrated in Figure 4.15A, where the universal sequence is tethered 
on magnetic beads from its 3’ end. We then went on to test this system’s role as an inhibitor during 
transcription reaction, due to its close relation to the previously published work where capture 
DNA was used to sequester the 3’ end of RNA. We recognized that product RNA would not sit 
blunt to capture DNA in this scenario, and dual capture DNA could be used as a template if 
polymerase extended RNA from its 3’ end in a trans primed extension reaction. Therefore, we 
used both dual capture DNA and universal sequence in the transcription reaction, so that their 
hybridization would prevent any such templated extension activity. 
In the presence of both oligos, we performed a 5-minute in vitro transcription generating 
RNA-24 using T7 RNA polymerase. The first lane in Figure 4.16A shows the transcription pool 
in the absence of dual capture DNA; two distinct RNA bands are observed indicating encoded 
RNA-24 and 3’ self-extended longer impurities. In the presence of dual capture DNA 1 and 
universal sequence 1, the cis primed extension products are no longer generated, however another 
longer RNA product is observed. While bead pull down assay only purified the encoded RNA, this 
longer product was generated and washed away from the beads, indicating it is probably free in 
solution (not binding to the beads). We hypothesized that this is due to templated addition on the 
3’ end of the RNA. After the RNA binds to the dual capture DNA 1, polymerase uses the dual 
capture DNA as a template and extends on the 3’ end of the RNA, displacing it from the universal 
sequence.   
To further investigate what this band referred to, we incubated a synthetic RNA-24 with 
the universal sequence DNA and dual capture DNA in the absence of promoter DNA and carried 
out transcription, as shown in Figure 4.16B. A long band migrating to the same position in the gel 
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was observed, likely the same band as observed before, indicating this band arose from promoter 
independent activity of polymerase. Since the 3’ end of RNA is free, and the RNA is bound to dual 
capture DNA, the most likely explanation is that the RNA was extended from its 3’ end. To further 
inspect the nature of this product, we treated the sample with DNAse 1. Upon digestion of DNA, 
we observed two new bands, one referring to the length of RNA-24, and other to a length not 
observed before. This suggests the longer band was an RNA:DNA chimera, consisting of two RNA 
strands and a short DNA strand binding them together. At this point, we could only speculate what 
non-promoter specific activity caused this band, as strand jumping activity may have been taking 
place as well. We are not sure of the mechanism, but we were sure that we needed to change the 
direction of the universal DNA sequence to prevent the 3’ end of the RNA from extension. 
To further investigate what this band referred to, we incubated a synthetic RNA-24 with 
the universal sequence DNA and dual capture DNA in the absence of promoter DNA and carried 
out transcription, as shown in Figure 4.16B. A long band migrating to the same position in the gel 
was observed, likely the same band as observed before, indicating this band arose from promoter 
independent activity of polymerase. Since the 3’ end of RNA is free, and the RNA is bound to dual 
capture DNA, the most likely explanation is that the RNA was extended from its 3’ end. To further 
inspect the nature of this product, we treated the sample with DNAse 1. Upon digestion of DNA, 
we observed two new bands, one referring to the length of RNA-24, and other to a length not 
observed before. This suggests the longer band was an RNA:DNA chimera, consisting of two RNA 
strands and a short DNA strand binding them together. At this point, we could only speculate what 
non-promoter specific activity caused this band, as strand jumping activity may have been taking 
place as well. We are not sure of the mechanism, but we were sure that we needed to change the 




Figure 4.16. Universal capture purification of RNA-24 using method introduced in Figure 15A. 
A. The effect of dual capture DNA 1 and universal sequence 1 on transcription of RNA-24 under 
low yield conditions, and the subsequent capture purification of RNA-24 on streptavidin beads. 
B. The effect of dual capture DNA 1 and universal sequence 1 presence near high yields of RNA 
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4.3.11. Blunt 3’ RNA. 
Exploring the second option in Figure 5.15, we designed a new universal sequence 2 and 
dual capture DNA 2 so that the 3’ end of product RNA will sit blunt to the 5’ end of the dual 
capture DNA. We then we performed high yield transcription in the absence of any capture DNA, 
as seen in the first lane in Figure 4.17. We then compared the effect of adding of dual capture DNA 
1 vs dual capture DNA 2 during transcription on the product RNAs. When dual capture DNA 1 
strand is added alone to the transcription reaction, polymerase participates in significant non-
promoter specific activity resulting in a large pool of heterogeneous, longer RNA products. Upon 
DNAse 1 digestion, most products get cleaved, and a heterogeneous pool of RNA products are 
observed. This is similar to the results we had seen in Figure 4.16, yet at an increased rate, since 
the reaction was run under high yield conditions in Figure 4.17, while the experiment in Figure 
4.16 was performed under low yield conditions. 
Changing both sequence and direction of the dual capture DNA, we performed 
transcription in the presence of dual capture DNA 2, as seen in Figure 4.17. Despite changing the 
direction of the dual capture DNA, and leaving RNA with a blunt end, not all promoter non-
specific activities are prevented. There is another impurity: a longer band, present as a result of 
this incubation. Upon DNAse treatment, these bands are digested, revealing a clean RNA-24 
encoded product. While it is not clear what these other bands were, they could be products of non-
promoter specific activity of T7 RNA polymerase. While making the dual capture DNA strand sit 
blunt to the 3’ end of the RNA helped prevent excess non-promoter specific activity of T7 RNA 
polymerase, it did not avoid all such activity. From the results in 4.17, we concluded that the 
universal affinity tag purification design was too complex to use such purification system during 
a transcription reaction. Given the unpredictable non-promoter specific activities of polymerase 
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and the number of free oligos in solution at high concentrations, we decided to not further pursue 
this strategy for transcription.  
 
Figure 4.17. Transcription of RNA-24 under high yield conditions in the absence and presence 
of dual capture DNA 1 and 2 and their consequent DNAse I treatment. Transcription under 
high yield conditions generated RNA-24 and extended products sans dual capture DNA 1 or 2. In 
presence of dual capture DNA 1, polymerase participates in significant non-promoter specific 
activity, resulting in much longer extended products. Upon DNAse I treatment, most of such 
bands get cleaved, leaving a heterogenous RNA product pool. In presence of dual capture DNA 
2, some longer bands are observed, but the majority of product is RNA-24. Upon DNAse I 
treatment, all other bands are cleaved except RNA-24. 
4.4 DISCUSSION 
Researchers across a wide swath of fields that use RNA require pure and high yields of 
pure, correct sequence RNA. While solid phase chemical synthesis can generate RNAs <100 nt in 
length (74), enzymatic synthesis in vitro by T7 RNA polymerase (23) is routinely chosen over 
chemical synthesis to synthesize high yields of RNA of all lengths. In either case, product RNA 
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out with either gel or chromatographic methods, which have their major disadvantages as 
described earlier (49–53). In this chapter, we introduced a novel affinity purification method using 
bead immobilized capture DNA to purify only desired RNA, while washing other RNA byproducts 
(i.e. abortives, truncated products, longer impurities, and reagents) away.  
4.4.1. Capture DNA immobilized on magnetic beads  
We designed a capture DNA that is complementary in sequence to the 3’ end of RNA-24 
and immobilized it on magnetic beads by the strong biotin-streptavidin reaction. Based on 
predicted melting temperatures (Tm’s), this capture DNA needed to be longer than ~15 nt to be 
able to effectively capture product RNA in a RNA:DNA hybrid. As predicted, bead immobilized 
capture DNA captured only the encoded RNA from a pool of diverse RNA products, as shown in 
Figure 4.2. For the purification of high yields of correct RNA, this method would need to be carried 
out in combination with one of the improved transcription reactions established in this dissertation, 
or with a previously published transcription method. We combined the previously published 
transcription strategy with our purification approach simply by carrying out transcription in the 
presence of the capture DNA, and immobilizing of the RNA:DNA hybrid post transcription on 
streptavidin magnetic beads. Results in Figures 4.3 and 4.4 showed that while this prevented the 
formation of extended products, and successfully purified the encoded RNA by their capturing on 
magnetic beads via the affinity tag, the intermediate RNAs also got co-purified as a result. In 
addition, the capacity of the commercially available streptavidin beads was not enough to purify 
high yields of RNA.  
To improve the capacity, we used Strep-Tactin®XT, as this bead is coated with 6% 
agarose, and therefore has higher capacity than the previously used streptavidin beads. As 
expected, high yields of RNA was captured on beads. Only 5 µLof dry bead tethered with 4 nM 
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of capture DNA oligo in a 10 µLtranscription reaction is predicted to be sufficient to inhibit self-
extension if used during transcription Further improvement on elution conditions needs to be 
performed for precise elution of RNA without denaturing the streptavidin protein coated on the 
beads.  One setback with the Strep-Tactin®XT beads could be that they are coated with 6% agarose 
around a magnetic core, and thus may not apply well to very long RNAs (such as mRNA), as the 
porosity of the beads may limit the ability of the RNA to reach the binding sites on the bead surface. 
For stability and reusability, one can obtain paramagnetic beads with DNA covalently attached to 
a non-porous bead surface. However, this design results in still lower binding capacity due to the 
lack of porosity.  
4.4.2. Increasing the binding sites DNA oligo immobilized on magnetic beads  
In a quest to improve the low binding capacity observed with streptavidin magnetic beads, 
we developed a novel system to increase the RNA binding sites available per capture DNA oligo 
bound on magnetic beads. We circularized a DNA and used it as a template to extend the capture 
DNA attached on the beads by rolling circle amplification reaction. We showed that this method 
is powerful and can bind high yields of RNA in solution, as demonstrated in Figure 4.9. However, 
we were unable to bind the RCA-generated, long DNA capture strand to the streptavidin beads, 
also shown in Figure 4.9. We hypothesized that either 1) the long DNA may be tangled in itself, 
burying the 5’ biotin tag in its core or 2) the size of the RCA-generated DNA does not allow it to 
enter the agarose pores. 
To address the second concern, we next tried a different magnetic bead that has T(25) oligo 
DNA covalently tethered on magnetic beads of low/no surface porosity. We used increasing 
ddNTP/dNTP concentrations to control the DNA length distribution of the RCA reaction, and 
tested for RNA binding. While we were able to perform RCA on the beads, as shown in Figure 
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4.13, we only purified a small concentration of RNA, as shown in Figure 4.14. This showed that 
the RCA efficiency on beads needed to be improved.  
This strategy could be used during or post synthesis, but just like other strategies what 
polymerase non-promoter specific activity polymerase may carry out is currently unknown. 
Taking from the results seen in Figures 4.16 and 4.17, perhaps the RNA bound on the long capture 
DNA oligo will be extended in a templated fashion, even if there are DNA oligos put in between 
the binding sites to prevent such activity. For the moment, it would seem best to first perform an 
improved in vitro transcription reaction (high salt tethered, or flow synthesis) and then follow up 
that reaction with this purification protocol for efficient and robust RNA purification.  
4.4.3. A universal reagent for the affinity tag purification of desired RNA  
We designed a universal system using a “universal sequence” tethered to magnetic beads 
that allowed customization of capture DNA for purification different RNA sequences. We showed 
in Figure 4.2 that capture DNA can purify only the encoded RNA from a pool of diverse products. 
It is expected that the universal reagent approach would bring similar results. However, we only 
worked on its effect as a purification agent during transcription reactions. Results in Figure 4.16 
demonstrated that not having a free end at the 3’ end of the RNA caused substantial non-promoter 
specific polymerase activity, resulting in the generation of an undesired long RNA:DNA chimera. 
Although changing the direction of this dual capture DNA improved the non-promoter specific 
polymerase activity substantially, it did not get rid of it completely, as seen in Figure 4.17. These 
results showed that this purifications method may not be ideal to be used during transcription. 
However, it can be very powerful for purification post transcription, in aiding customization for 
diverse sequence of RNAs using the same universal purification platform. In order to achieve high 
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yields of RNA purification, and to prevent its wasteful conversion to longer impurities, one would 
need to use one of the improved transcription methods established in this dissertation first.  
4.5 SUMMARY 
In this research, we develop a novel affinity tag method for the purification of in vitro 
transcribed RNA in high yields. Magnetic bead immobilized capture DNA is complementary to 
the 3’ end of the RNA to be purified. We first demonstrate that the affinity tag can selectively 
purify only the desired RNA from a pool of heterogeneous RNA products. We then show that the 
capture DNA can be used during transcription, as previously demonstrated (47) to RNA self-
primed extension. We further improved this methodology by incubating the crude reaction mix 
with streptavidin beads post transcription to purify only the desired RNA. We found that using 
streptavidin beads has low capacity, making them inefficient in their application to high yield 
transcription reactions. We observed this initial system may co-purify the intermediate RNA 
byproducts as well. We improved on this fallback by using a higher capacity bead system. Strep 
Tactin-XT® magnetic beads demonstrated to efficiently capture and purify high yields of synthetic 
RNA.  
These initial findings helped us understand the major challenge of the project: which is to 
find a magnetic bead with high capacity to be able to purify large quantities of encoded RNA. 
However, magnetic beads often lack the porosity required to enable high-capacity capabilities. For 
this reason, I designed a novel capture purification method to improve the capacity of any bead 
used for affinity purification of in vitro transcribed RNA. In this method, we improve the binding 
capacity by using rolling circle amplification to increase the binding sites per DNA oligo bound 
on beads. The capture DNA oligo sequence is repeated in tandem for many rounds, and encoded 
RNA binds to these sites.  
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Next, we developed a novel universal capture DNA purification system that could be used 
for any sequence of RNA to be captured without having the researcher change the system to fit 
their sequence needs. In this system, a “universal DNA oligo” with a fixed, universal sequence is 
immobilized on magnetic beads by its 3’ end. “Dual capture DNA” has sequence complementarity 
to both the universal DNA oligo sequence and to the 3’ end of the desired RNA to be purified. We 
demonstrated that the method can indeed capture purify encoded RNA, as hypothesized. This 
method is more suited for purification post transcription, since its presence during transcription 



















































































































































































































































































































































































































































































































































































































A NOVEL MICROFLUIDIC RNA MICROFACTORY GENERATES HIGH YIELD RNA 
WITH SUPERIOR PURITY 
 
5.1 INTRODUCTION 
The mRNA therapeutics industry has finally evolved from being a “future promise,” to an 
applicable therapy. The urgency of the COVID-19 pandemic has accelerated the establishing of 
safe and effective RNA vaccines, putting a spotlight on what mRNA therapeutics can offer to the 
world from vaccines to genetic diseases. Until recently, mRNA therapeutics was not an applicable 
therapy and most researchers only produced small amounts of RNA sufficient for their research 
purposes. Now, the field has matured into a treatment modality. In this new light, generating high 
yields of pure RNA in an automated way emerges as a novel need of the industry.  
Currently, all mRNA and most other RNAs are routinely generated by in vitro transcription 
using T7 RNA polymerase. This is a simple, highly efficient and low-cost method to generate high 
yields of long (and short) RNA (18, 20, 23, 66). However, in vitro transcription by T7 RNA 
polymerase is a complex and multi-step process and the product profile is often heterogeneous due 
to enzyme promiscuity (20, 25, 31, 32, 34, 37–39, 41, 42, 44, 45). While this enzyme can produce 
high yields of desired RNA, it also produces short RNAs 2-7 nt in length (abortive cycling) (30, 
46), and longer than directly encoded RNAs via a wide array of mechanisms explained in further 
detail in Chapter 1. 
Under high yield transcription conditions, when large quantities of RNA accumulate near 
T7 RNA polymerase, the enzyme partakes in significant RNA rebinding and subsequent cis-
primed extension activities (31, 32). As a result, the product profile is often contaminated with a 
heterogeneous pool of partially and fully double stranded RNA products. As industry requires high 
yields of RNA for various treatment modalities (such as mRNA vaccines), double stranded RNA 
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byproducts are often the most cumbersome impurity in large-scale RNA production (60, 62, 65, 
69). Therefore, while T7 RNA polymerase is praised for being an easy, low-cost method to produce 
high yields of RNA, the quest for high yield only exacerbates the generation of long, double 
stranded RNA impurities (31, 32).  
RNA therapeutics companies such as Moderna and BioNTech routinely follow high yield 
transcription with extensive HPLC purification(60–63) to rid the product pool of short and long 
RNA impurities. In addition to routine purification, they also take advantage of other 
methodologies, such as the use of synthetic nucleotides (e.g., pseudo (ψ)-UTP), to further prevent 
the immune response caused by double stranded impurities (99–101). The limitations of current 
purification methodologies and other immune response prevention techniques are explained in 
further detail in Chapter 1.  
In short, current methodologies for high yield RNA synthesis and purification, adopted 
from protocols established decades ago, are simply not enough to carry the RNA therapeutics field 
to where it can lead. Current protocols of transcription and purification need to be improved for 
industrial scale, ultrapure RNA generation.  
In Chapter 3, I introduced a novel high salt in vitro transcription method where T7 RNA 
polymerase and promoter DNA are co-tethered on magnetic beads. I demonstrated that while high 
salt dramatically reduces all nucleic acid-polymerase interactions, co-tethering T7 RNA 
polymerase and promoter DNA in proximity on beads restores only promoter-driven transcription 
and limits the RNA rebinding activity of polymerase. Using this method, only encoded RNA is 
generated at high yields. The immobilized system is reusable up to at least three times, providing 
further improvement in overall yield. Whilst this system is superior in terms of purity and yield to 
the generic method, it can be further improved for automated use in industry.  
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To prevent primed extension of accumulating RNA, we now aim to not allow the RNA to 
accumulate near the enzyme from the outset. In this Chapter, I introduce a novel microfluidic in 
vitro transcription device. The bead-tethered transcription system (established in Chapter 3) is 
trapped inside the reaction chamber of a fluidics device. Transcription is carried out under 
continuous flow, allowing product RNA to flow out of the device continuously, preventing its 
accumulation near the polymerase. We expect this approach to reduce the production of longer, 
double stranded RNA impurities substantially, even at low salt, while producing high yields of 
encoded RNA. We predict this approach will revolutionize the large-scale generation of pure RNA 
for industry and serve as a gateway for revolutionizing many other manufacturing methodologies 
in biotech and pharma companies. 
5.2 MATERIALS AND METHODS 
5.2.1 Reagents  
DNA oligonucleotides used in transcription reactions were purchased from Integrated 
DNA Technologies (IDT). The following buffers in Table 5.2.1 were optimized in house and used 
where indicated.  
 










HEPES, pH 7.8 - 30 mM 30 mM
Tris-HCl, pH 7.5 20 mM - -
Magnesium acetate - 15 mM 40 mM
Potassium glutamate - 25 mM 25 mM
Tween 20 - 0.05% 0.05%
EDTA 1 mM 0.25 mM 0.25 mM
Pyrophosphatase - - 10 U/mL
NaCl 0.5 M -
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5.2.2 T7 RNA polymerase 
His-tagged T7 RNA polymerase was prepared from Escherichia coli strain BL21 carrying 
the plasmid pBH161; purified and characterized as previously described (29). 
5.2.3 Strep-T7 RNA polymerase 
In an earlier, unpublished work, an ATG start codon, the Strep-tag® II sequence 
(WSHPQFEK) and a linker sequence (GGS) (followed by the T7 RNA polymerase gene) were 
inserted between the Nco I and Hind III restriction sites in the plasmid vector pBAD HisA. Strep 
tagged T7 RNA polymerase was expressed under the inducible control of the L(+) arabinose 
promoter, and further purified using Strep-Tactin® protein purification resin from IBA 
technologies.  
5.2.4 Manufacturing of the Microfluidic Device Mold 
Device designs were drawn on Adobe Illustrator. Photomask was printed at 20K DPI 
resolution with clear field right reading down orientation (CFRRD) (Fineline Imaging, Inc). 
After SU-8 2100 photoresist coated wafer was spun at 3000 RPM to a thickness of 100 µm, it was 
pre-baked at 65°C and 95°C. Then, the photomask was covered over the coated wafer and exposed 
to ultraviolet (UV) light with an exposure energy of 240 mJ/cm2 to crosslink the photoresist. After 
exposure, it was baked again at 65°C and 95°C. The unexposed parts were removed by propylene 
glycol monomethyl ether acetate (Sigma Aldrich).  
5.2.5 Manufacturing of the PDMS-Glass Microfluidic Device  
A 1 cm thick PDMS (Sylgard® 184 from Dow Corning®) was prepared by 10:1 ratio of 
elastomer base to curing agent, degassed for 40 minutes in a vacuum chamber and cured on the 
device mold for at least 2 hours at 80°C. The PDMS with the design imprint was cut from the 
mold, inlet and outlet holes were punched. The PDMS was bonded to a glass slide by oxygen 
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plasma treatment (Harrick Plasma Cleaner). The flow system was assembled by connecting tubes 
directly to the inlet and the outlet. To interchange between different reagent flows to the inlet, two 
Y-valves were connected prior to the inlet port to allow for reagent switching. Device features 
were observed with Amscope 7X-45X Dual Lit 6W LED Trinocular Stereo Zoom Microscope and 
images were taken with a 10MP USB 2.0 Color CMOS C-Mount Microscope Camera with 
Reduction Lens attached. 
5.2.6 Batch transcription reactions 
High yield batch in vitro transcription reactions (1 h reaction in Figure 5.3.7B) were 
performed with high yield transcription buffer in presence of 0.8 μM (each) of nontemplate and 
template DNA, 0.8 μM T7 RNA polymerase and 7.5 mM of each NTP, in an overall 20 μL reaction 
volume at room temperature. Low yield batch in vitro transcription reactions (5 min reaction in 
Figure 5.3.7B) were performed with T7 RNA polymerase buffer in presence of 0.8 μM (each) of 
nontemplate and template DNA, 0.8 μM T7 RNA polymerase and 0.8 mM of each NTP. 
Transcription reactions were stopped by heat denaturation at 95 °C for 5 min.  
5.2.7 Preparation of bead co-tethered system before packing  
To assemble the promoter complex, equimolar (0.8 µM final) concentrations of 
biotinylated nontemplate DNA, template DNA and Strep-T7 RNA polymerase were incubated at 
4 °C for 30 min in T7 RNA polymerase buffer. Strep-Tactin®XT (5% slurry) beads were washed 
with T7 RNA polymerase buffer three times and then incubated with the above enzyme-promoter 
comple at 4 °C overnight in a rotator to form the tethered transcription system. After overnight 
incubation, tethered transcription system was washed twice with wash buffer and once with T7 
RNA polymerase buffer to rid the system of any untethered system components.  26 µL of a 1% 
v/v bead slurry (MagStrep “type3” XT beads, IBA Lifesciences) netting approximately 0.26 µL 
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packed beads tethered with 0.8 µM final concentrations biotinylated nontemplate DNA, template 
DNA and Strep-T7 RNApolymerase of transcription complex were incubated in T7 RNA 
polymerase buffer containing 10% PEG-8000 to homogenize the bead co-tethered system for 
packing. All reactions were assembled with specific promoter DNA sequences as indicated in text. 
5.2.8 Flow transcription reactions 
In all flow reactions, low yield reaction conditions were used. Transcription was initiated 
with the inflow of T7 RNA polymerase buffer containing 0.8 mM of each NTPs at room 
temperature at flow rates and times as indicated in text. Fractions coming from the outflow were 
collected every 5 minutes and heat denatured at 95 °C for 5 min.  
5.2.9 Gel electrophoretic analyses 
All reactions were analyzed by 15% polyacrylamide (19:1 acrylamide:bisacrylamide) 
denaturing (7M) urea gel electrophoresis, labeled with SYBR™ Gold Gel Stain (Invitrogen) and 
imaged with a Gel Doc Go Imaging System Blue Tray (Bio-Rad). 
5.3 RESULTS  
The goal of this study is to prevent the accumulation of encoded RNA near T7 RNA 
polymerase and therefore eliminate RNA rebinding and cis-primed extension activities of 
polymerase. Here, we establish a novel microfluidic in vitro transcription device that continuously 
generates high yields of RNA and concomitantly carries it away from T7 RNA polymerase. 
Transcription operates under continuous flow in a reaction chamber, where a bead co-tethered 
transcription complex (established in Chapter 3) is physically trapped by an array of micropillars. 
As transcription proceeds under continuous flow, promoter DNA and T7 RNA polymerase (bound 
to beads) are retained inside the reactor chamber, while all products (including RNA) flow out 
(while fresh reagents are continuously introduced). As product RNA is removed from the 
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microfluidic device as soon as it is generated, its accumulation near T7 RNA polymerase is 
prevented. We expect this novel approach to generate high yields of only encoded RNA, and 
prevent the generation of longer, double stranded impurities.  
5.3.1. Design of a microfluidic in vitro transcription device 
In order to trap the bead-tethered system established in Chapter 3 inside a microfluidic 
device and still allow for efficient transcription and continuous outflow of product RNA, I first 
designed a single inlet-single outlet PDMS-glass device with a single array of PDMS micropillars 
near the outlet, as shown in Figure 5.3.1A. The micropillar array acts as a barrier to trap the beads, 
while allowing free flow of product RNA away from the polymerase with continuous flow. In 
order to trap the Strep Tactin-XT® beads that have an average diameter of 25 µm, the lateral 
spacings between the micropillars are designed to be 20 µm (the micropillars are 40x50x100 µm 
in width, length and height, as shown in Figure 5.3.1B). We hypothesized this to be sufficient for 
efficient trapping of the beads, while still allowing continuous flow.  
I designed the microfluidic device dimensions accordingly to accommodate the packing of 
26 µL of a 1% v/v bead slurry (MagStrep “type3” XT beads, IBA Lifesciences) netting 
approximately 0.26 µL beads (calculated value). The reaction chamber of the microfluidic device 
that hosts all of the bead-tethered transcription complex is designed as 6.6 mm in length, 600 µm 
in width and 100 µm in height, netting to about 0.4 µL chamber volume capacity, as shown in 
Figure 5.3.1B. I selected channel height to be 100 µm, that is four times the bead diameter, in order 





Figure 5.3.1. Design of a microfluidic transcription device. A. Scheme of a PDMS-glass 
microfluidic in vitro transcription device. B. Design of the PDMS-glass microfluidic in vitro 
transcription device. Transcription is initiated with the inflow of T7 RNA polymerase buffer, 
containing NTPs. Beads (tethered with promoter DNA and T7 RNA polymerase system) are 
trapped in reaction chamber by an array of micropillars. Product RNA, and other biproducts in 
transcription buffer are flowed out as generated. Reaction chamber and bead dimensions are as 
shown. C. Design of the bead tethered transcription complex. Strep-T7 RNA polymerase and 
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5.3.2. Fabrication of the microfluidic in vitro transcription device 
We drew the microfluidic device design using Adobe Illustrator and printed the photomask 
at 20K DPI resolution with clear field right reading down orientation (CFRRD) (Fineline Imaging, 
Inc). After SU-8 2100 photoresist coated wafers were spun at 3000 RPM to a thickness of 100 µm, 
photomask was covered over the coated wafer and exposed to ultraviolet (UV) light with an 
exposure energy of 240 mJ/cm2 to crosslink the photoresist. The unexposed parts were removed 
by treatment with propylene glycol monomethyl ether acetate (Sigma Aldrich).  
A 1 cm thick polydimethylsiloxane (PDMS) (Sylgard® 184 from Dow Corning®) sheet 
was prepared with a 10:1 ratio of elastomer base to curing agent, degassed for 40 min in a vacuum 
chamber and cured on the SU-8 mold for at least 2 hours at 60°C. After the PDMS sheet with the 
design imprint was cut from the mold, the inlet and outlet holes were punched, and the sheet was 
bonded to a glass slide by oxygen plasma treatment (Harrick Plasma Cleaner). The flow system 
was assembled by connecting tubes directly to the inlet and the outlet holes. To interchange 
between different reagent flows to the inlet, two Y-valves were connected prior to the inlet port to 
allow for reagent switching. Figure 5.3.2B demonstrates the glass-PDMS microfluidic device with 
the naked eye. Figure 5.3.2C shows the device with all its micropillar features using a stereoscope 
(image taken with a 10MP USB 2.0 Color CMOS C-Mount Microscope Camera with Reduction 
Lens attached to an Amscope 7X-45X Dual Lit 6W LED Trinocular Stereo Zoom Microscope). 
With the device functionally fabricated, we tested for any leakage using a syringe pump and yellow 








Figure 5.3.2. Microfluidic device fabrication A. Design of the PDMS-glass microfluidic in vitro 
transcription device. Reaction chamber length (l): 6.6 mm, height (h): 100 µm, width (w): 600 
µm. Micropillar dimensions (d): 40X50 µm, separated by gaps of (g): 20 µm. B. Picture of the 
PDMS-Glass microfluidic transcription device, with mm markers above the channel for scale. C. 
A closer picture of the microfluidic device taken with 10MP USB 2.0 Color CMOS C-Mount 
Microscope Camera with Reduction Lens attached to an Amscope 7X-45X Dual Lit 6W LED 
Trinocular Stereo Zoom Microscope. D. Picture of the yellow food dye flowing through the 
microfluidic device.  
5.3.3. Packing the microfluidic device with bead-tethered transcription complex 
Having demonstrated that the device was fabricated as intended, we proceeded to test the 
trapping of the beads in the reaction chamber. The lateral gap between each micropillar in the array 
is 20 µm, and the average bead diameter is 25 µm. With this design, we expect near complete 
trapping of the beads inside the reaction chamber without leakage. Given that the beads are 
magnetic, we predicted the beads could potentially stick to each other. This could cause their 
clumping and clogging the inlet. We hypothesized that homogenizing the beads in a viscous 
solution would prevent any possible clumping of the magnetic beads. To test the hypothesis, we 
regenerated beads in T7 RNA polymerase buffer in final concentrations of 1% v/v bead and 10% 











5 µL/min using a syringe pump. Figure 5.3.3B shows efficient packing of the beads in the 
microfluidic device without significant clogging at the inlet, as hypothesized.  
 
Figure 5.3.3. Packing the microfluidic device with bead-tethered transcription complex A. 
Bead-tethered transcription complex is homogenized in a viscous solution of 10% PEG-8000, 1% 
bead v/v. B. Homogenized viscous bead solution is loaded into the reaction chamber with 
positive flow using a Harvard PHD Ultra syringe pump at 5 µL/min flow rate. 
5.3.4. Microfluidic in vitro transcription using fully double stranded promoter DNA 
generates encoded RNA 
We next tested the system for microfluidic in vitro transcription. We packed 0.26 µL bead-
tethered transcription system with fully double stranded promoter DNA in T7 RNA polymerase 
buffer containing 10% PEG-8000 to a final 1% v/v into the microfluidic device at 5 µL/min using 
a syringe pump. After packing, we washed the system with T7 RNA polymerase buffer for 5 mins 




Positive Flow into 
micro!uidic device






containing 0.8 mM of each NTP at 5 µL/min. We did not need to use high yield transcription buffer 
and high NTP concentrations to generate high yields of RNA, since fresh NTPs are continuously 
introduced to the system with the incoming flow. Similarly, we omitted pyrophosphatase as 
pyrophosphate is continuously removed from the reactor. 
In order to test transcription activity over time, we took fractions of products every 5 
minutes. We selected the fractions taken at 5, 15, 25 and 35 mins to analyze for RNA products in 
15% polyacrylamide 7M urea denaturing gel stained with SYBR™ Gold Gel Stain, as shown in 
Figure 5.3.4B. The prominent bands for the 24 base encoded RNA indicate that the tethered system 
is functional in the microfluidic device. Under the flow rates used, T7 RNA polymerase initiates 
transcription well, without impaired promoter clearance or elongation. Aside from the encoded 
RNA product, we also observed smearing of longer products. This suggests some cis primed 
extension of the encoded RNA, as seen before for this construct in batch transcription reactions in 
Chapter 2. In addition, we observed a sharp band, noted in the Figure 5.3.4, hypothesized to be 
either prime extended RNA impurity (as seen in Chapter 2), or template DNA, judging by its 
apparent length. While product profiles are similar for fractions taken before 15 min, the overall 
yield drops significantly after this time point. This apparent inactivation suggests significant loss 
of some component in the transcription complex under fluidic conditions, perhaps the template 





Figure 5.3.4. Microfluidic in vitro transcription using fully double stranded promoter DNA 
generates encoded RNA. A. Bead tethered transcription complex. Strep-T7 RNA polymerase 
and biotinylated fully double stranded promoter DNA are co-tethered on Strep-Tactin-XT® 
beads. B. Fifteen percent denaturing 7 M urea gel stained with SYBR™ Gold Gel Stain. Fractions 
taken from products fluidics in vitro transcription under 5 µL/min flow rate generating RNA-
24Alt using microfluidic setup shown in panel A.  
5.3.5. Tight binding promoter DNA [pss-5] retains tethered system components 
under flow conditions 
In the bead tethered system, template DNA is only retained by promoter affinity and by 
duplex DNA contacts. In this flow application, the DNA duplex is only 44 bases in length and so 
transient dissociation, perhaps facilitated by polymerase-mediated local melting(102), could lead 
to continuous loss of small amounts of template DNA. On the other hand, strong promoter binding 
would stabilize the complex against dissociation. In Chapter 3, I demonstrated that strengthening 
promoter binding in the tethered system by using partially single stranded DNA [pss-5] allows for 




















greater persistence of the complex during each washing step of the (batch) reusability experiments. 
Therefore, we hypothesized that using partially single stranded promoter construct [pss-5] would 
strengthen promoter affinity, and retain the entire complex tethered on beads, allowing sustained 
synthesis under flow. Accordingly, we repeated the experiment demonstrated in Figure 5.3.4B 
using partially single stranded DNA [pss-5]. As described in further detail in Chapter 2 and 3, this 
promoter DNA has at least four times more affinity for promoter DNA, and also much lower koff 
values (90–92). This stronger binding could prevent (or limit) the dissociation of template DNA 
under flow conditions.  
As expected, the results presented in Figure 5.3.5. show continuous RNA production, with 
more retention in yield over longer times, relative to the results in Figure 5.3.4B. Thus, use of the 
bead-tethered pss[-5] promoter DNA allows synthesis of RNA over at least 35 minutes, with much 
improved yield of RNA over the entire time course. Moreover, the band predicted as template 
DNA is not observed as prominently, suggesting it is retained better during flow, as predicted. 
Alternatively, if the sharp band refers to a cis prime extended RNA impurity, using the tighter 





Figure 5.3.5. Continuous RNA production without significant loss in yield using pss[-5] 
promoter DNA A. Scheme of a microfluidic in vitro transcription device packed with beads co-
tethered with T7 RNA polymerase and promoter DNA using pss[-5] nontemplate. B. Fifteen 
percent denaturing 7 M urea gel stained with SYBR™ Gold Gel Stain. Fractions taken from 
products fluidics in vitro transcription under 5 µL/min flow rate generating RNA-24 using 
microfluidic setup shown in panel A.  
5.3.6. Decreased flow rate allows synthesis of primer-extended RNA 
The use of pss[-5] promoter DNA both increases complex stability and, as seen in Chapter 
3, reduces primer extension. The primary aim of the flow approach is to further reduce primer 
extension by removing product as it is synthesized. This latter effect is expected to depend on flow 
rates: slower flow rates will allow the product RNA to accumulate in the chamber more than faster 
flow rates. At the above flow rate of 5 µL/min, we observe some cis primed extension activity, 
even for the pss[-5] construct. The model predicts that reducing the 5 µL/min flow rate to to 1 





















confirm that at this lower flow rate, there is significantly more accumulation of both encoded RNA-
24 and 3’ self-extended longer, double stranded RNA. This result suggests that at flow rates of 1 
µL/min, RNA is not removed from the reaction chamber fast enough to prevent its accumulation 
and rebinding by T7 RNA polymerase. Using higher flow rates resulted in an overall loss of 
transcription (results now shown), predicted as a result of washing off of a system component.  
 
Figure 5.3.6. Increasing flow rate reduces RNA accumulation in reaction chamber, preventing 
RNA 3’ self-extension A. Scheme of a microfluidic in vitro transcription device and tethered 
transcription system with pss[-5] nontemplate. B. Fifteen percent denaturing 7 M urea gel 
stained with SYBR™ Gold Gel Stain. Fractions taken from products fluidics in vitro transcription 
under 1 µL/min flow rate generating RNA-24 using microfluidic setup shown in panel A. C. 
Fifteen percent denaturing urea gel stained with SYBR™ Gold Gel Stain Fractions taken from 
products fluidics in vitro transcription under 5 µL/min flow rate generating RNA-24 using 
microfluidic setup shown in panel A. 
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5.3.7. Comparison of batch and flow synthesis 
Finally, we compared the product profiles of the fluidic in vitro transcription reaction with 
low and high yield batch in vitro transcription reactions. For low and high yield batch in vitro 
transcription batch reactions, we used untethered, partially single stranded promoter DNA [pss-5], 
and T7 RNA polymerase at 0.8 µM final concentrations. Fluidic in vitro transcription reaction was 
carried under the same conditions as in Figure 5.3.5. In the comparisons presented in Figure 5.3.7, 
the batch 5 min in vitro transcription reaction was initiated with T7 RNA polymerase buffer and 
0.8 mM NTPs while the batch 1 h in vitro transcription reaction was initiated with high yield 
transcription buffer and 7.5 mM NTPs. The batch 1 h in vitro transcription reaction was diluted 
20-fold (note the reduction in the template DNA band) to compare yields with the batch 5 min in 
vitro transcription and the results reveal similar product profiles. It is important to note that, as 
demonstrated earlier in Chapter 2, using partially single stranded promoter DNA [pss-5] as 
opposed to [pss+2] prevents the RNA rebinding and extension activities even without added salt. 
For this reason, the overall improvement of encoded RNA production with fluidic in vitro 
transcription is not as significant here as it was in methodologies demonstrated Chapters 2 and 3. 
In batch transcription product lanes, there are two sharp bands where 24 base RNA would run, 
indicating the prominent production of RNA-24, with slower migrating products at lower 
intensities, suggesting some primer extension. These profiles are quite similar to the ones we 
observed in low salt transcription in Chapter 2, where we used pss[-5] to drive T7 RNA polymerase 
affinity to promoter. The two sharp bands and the longer smear are highly identical to that profile, 
as expected.  
Under flow conditions, sampling at 5 min, the higher of the two sharp bands is not 
generated as much and therefore the lower band (suggested 24 nt encoded RNA product) has an 
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increase in yield when compared with batch products. While the yield of encoded-length RNA is 
the highest under these conditions, there are still some extended products observed (we also see a 
small release of template DNA, as previously observed at 5 µL/min flow rates). Future studies will 
tune the flow rates to optimize purity and yield.  
 
Figure 5.3.7 Comparison of Batch and Flow Transcription Profiles and Yield. Transcription 
product RNA-24 from 5 min and 1 h batch reactions and a flow reaction sampled at 5 min are 
shown. Batch 1 h was diluted 20-fold to allow for purity comparisons with the batch and flow 5 
min product yields. Products were analyzed by 15% acrylamide, 7M urea denaturing gel 
electrophoresis, and detected via SYBR™ Gold gel staining. 
5.4 DISCUSSION  
In Chapter 3, we established a novel methodology that generates high yields of only 
encoded RNA without the double stranded impurities—reducing the need for extensive 
purification post synthesis. Now that RNA therapeutics is in the forefront of medicinal 
breakthrough, we need to further improve methodologies for automated mass production of highly 
pure RNA. 
In this Chapter, we establish a novel, automated microfluidic in vitro transcription device to 











bead-tethered transcription complex (established in Chapter 3) is contained inside the reaction 
chamber of a microfluidic device designed for this study. Transcription starts with the inflow of 
transcription reagents into the reaction chamber. Encoded RNA is generated and simultaneously 
removed from the reaction chamber with continuous flow, while the bead-tethered transcription 
complex is contained within the reaction chamber. As a result, RNA accumulation near the 
polymerase is limited, and so is the generation of longer, double stranded RNA impurities.  
5.4.1 A novel microfluidic in vitro transcription device  
The images shown in Figure 5.3.2 of the microfluidic device designed in Figure 5.3.1 
illustrate that this design can be easily manufactured using standard soft lithography techniques. 
We optimized the system to efficiently deliver the beads into the reaction chamber by first 
homogenizing them in a buffer containing 10% PEG-8000 to prevent their clogging in the device 
inlet. We successfully packed about a calculated volume of 0.26 µL beads in the reaction chamber, 
as shown in Figure 5.3.3. While bead-blocking micropillars retain the beads, lateral spacing 
between micropillars allows for unrestricted flow of solution.  
Results in Figures 5.3.4 and 5.3.5 clearly demonstrate efficient on-bead synthesis under 
flow conditions. It is interesting to note that with a reactor volume of about 0.4 µL (packed with 
an approximate amount of 0.26 µL beads) and a flow rate of 5 µL per min, the reactor undergoes 
a complete exchange of buffer about 12.5 times per minute. In 4 minutes, a total of 20 µL would 
get introduced into the system, equaling to the total NTP amount a 20 µL low yield batch reaction 
would use. This compares nicely with the overall yield of 5 min batch and flow products 
demonstrated in Figure 5.3.7. The overall yields of transcription are similar between the flow and 
5 min batch reactions. It is important to note that the flow conditions generate more of the 24 nt 
encoded RNA when compared with the batch 5 min. This is due to the prevention of RNA 
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accumulation in solution. Similarly, 1 hr batch reaction produces a similar profile of RNA products 
as the 5 min batch. We can conclude that flow reaction generates RNA with superior purity when 
compared with batch reactions.  
5.4.2 Strengthening promoter contacts using pss[-5] helps retain template DNA on 
beads, allows for longer transcription runs 
To a first approximation, since polymerase and the nontemplate strand of the DNA should 
be tightly bound to the beads, transcription should occur indefinitely. However, since this is a flow 
system, even transient dissociation of one component of the reactor will slowly lead to depletion 
of that component in the chamber. The cartoon in Figure 5.3.1C illustrates four main forces holding 
the reactor complex together: 1) biotin-Strep Tactin-XT® interaction, 2) Strep Tag II®- Strep 
Tactin-XT® interaction, 3) DNA:DNA duplex, 4) promoter DNA-polymerase interaction. These 
main forces together ensure tight binding of the complex together (note that the template strand is 
tethered only indirectly to the beads). In Figure 5.3.4B, denaturing gel front shows the products 
from the fluidic in vitro transcription where a bead-tethered system with fully double stranded 
promoter DNA was employed. The data presented in Figure 5.3.4B clearly demonstrate that RNA 
is efficiently synthesized on the beads under continuous flow using a bead-tethered system with 
fully double stranded promoter DNA. From the size markers, we are able to see product RNA, 
extended double-stranded RNA impurities, and a longer sharp band size of the template DNA (that 
could be both longer RNA impurities or washed off template DNA). In an ideal reactor, synthesis 
would be continuous for extended periods, allowing for high total yields of RNA per enzyme-
DNA complex, much higher than could be achieved in a conventional batch reactor. While 
transcription is continuous for 15 min, by 35 min, the yield of RNA decreases significantly using 
a bead-tethered system with fully double stranded promoter DNA.  
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It is well known that the pss[-5] construct binds RNA polymerase with about ten-fold 
stronger affinity than the fully double stranded promoter DNA (93, 103). More importantly, it 
shows a substantially reduced dissociation kinetic rate constant. Thus, we expect the promoter 
bound complex to be more resistant to flow(90–93, 103). As expected, the transcription with the 
immobilized pss[-5] construct shown in Figure 5.3.5 demonstrates notably longer transcription 
runs.  
The use of this construct provides an additional benefit clearly visible in Figure 5.3.5. As 
initiation is mostly a kinetic event, the reduced kinetic dissociation rate of pss[-5] promoter DNA 
directly correlates to the strengthening of promoter binding. This helps initiation to compete better 
with the rebinding of RNA to drive primer extension, yielding a higher ratio of encoded 24mer to 
longer primer extension products. 
5.4.3 Increased flow rate prevents RNA accumulation near T7 RNA polymerase 
eliminating its cis primed extension activity 
 In either of the above scenarios, faster flow rates will carry away any transiently dissociated 
reactor components. Thus, although the promoter contacts were strengthened by using the pss[-5] 
construct, overall transcription is clearly decreasing at 35 minutes (longer times were not tested). 
This suggests that at 5 µL/min flow rate, some template DNA could be lost under flow despite 
using pss[-5] to strengthen its promoter contacts. 
In order to reduce the depletion of the fully assembled reactor, we next reduced the flow 
rate from 5 to 1 µL/min. The results shown in Figure 5.3.6 show that at this lower flow rate, 
transcription continues at a good rate out to at least 55 min. However, the extended transcription 
occurs at a cost of overall purity. This is expected, since the lower flow rates allow RNA 
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concentrations within the reaction chamber to rise to higher levels, driving product rebinding to 
the polymerase.  
While continuous flow should remove encoded RNA from near polymerase that generated 
it, it is important to note that the 6.6 mm long reaction chamber is packed with 0.26 µL of beads 
along the channel. It is reasonable to predict that tethered complexes upstream of the reactor bed 
(closer to inlet) generate primarily encoded RNA. Farther along the reactor bed, at 1 µL/min flow, 
RNA products accumulate both from local synthesis and from upstream synthesis, such that RNA 
accumulating closer to the outlet can rebind the polymerase to generate primer extended products, 
resulting in longer impurities.  
The results in this Chapter clearly demonstrate the continuous synthesis of encoded RNA 
in a flow reactor. At sufficiently high flow rates, RNA should not accumulate substantially, 
yielding both higher purity and higher overall yield of the encoded RNA. However, lower flow 
rates may more efficiently consume substrate NTPs. In order to compensate for lower flow rates, 
RNA rebinding could be inhibited by adding salt in the buffer, as described in Chapters 2 and 3. 
With co-localized tethering of pss[-5] 
promoter DNA (for its strong promoter 
affinity) and RNA polymerase we predict that 
the reactor could be run at elevated salt 
concentrations, as demonstrated in Chapters 2 
and 3. Since transcription under 1 µL/min 
flow rate seems to be generating more RNA 
overall at longer times without significant loss 
in overall yield, at this point, an end user can 
 
Figure 5.3.8. Potential next generation 
parallel reactor configuration. A) current 
design; B) parallel reactors allow for shorter 






adjust the flow rate to balance the need for yield versus purity. A good tradeoff would be using a 
slow flow rate such as 1µL/min and combining it with a transcription buffer with ~0.2-03 M added 
NaCl, as demonstrated to be an effective implementation in producing clean RNA, discussed in 
further detail in Chapter 3. 
If under such conditions, there is still significant loss in yield due to washing of system 
components, future researchers may choose to use recently developed Strep-Tactin®XT 
Superflow® high-capacity resin, as it can be used under low pressure flow conditions. 
Alternatively, next generation devices may incorporate shorter reactor beds in parallel (i.e., multi-
channel or stacked devices for high yield output (104, 105), as illustrated in Figure 5.3.8. 
5.4.4 Device produces comparable RNA yield to high yield batch in vitro 
transcription reactions 
The experiments shown in Figure 5.3.7 compare product profiles of batch and flow in vitro 
transcription reactions. Flow in vitro transcription at a 5 µL/min flow rate generated significantly 
more encoded RNA when compared with batch reactions and low and high yield conditions 
without loss in overall yield. When comparing the yields between the 1 hr batch and flow products, 
we can compare the NTPs used by high yield batch and flow systems to conclude an estimate of 
overall time needed to generate the same amount of RNA. 1 hr batch reactions use 7.5 mM of each 
NTPs. For the flow system to get introduced with this much NTPs, the system would need to get 
187.5 µL of 0.8 mM NTPs introduced. Since the rate of flow is 5 µL per min, this would equal to 
a total time of 37.5 minutes. That said, if the transcription rate is similar between both systems, in 
37.5 minutes, the flow system would expectedly generate the same amount of RNA that high yield 
batch transcription would generate under longer times (i.e., 4 hours). This is clearly a benefit when 
considering the time cost of high yield batch transcription reactions. 
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Given that flow is productive for 35 minutes and uses ~9.4 times less NTP per volume, if 
flow reactor was introduced with a total of 187.5 µL NTPs in 37.5 minutes, it would expectedly 
generate the same RNA spread out over ~9.4x volume. The time savings of the flow is obvious 
here. If the influx of transcription reagents continued, flow would generate ~6.5 times RNA in 4 
hours when compared with the high yield batch reactions. The time savings and yield increase of 
the flow device then, is superior by a significant multiple.  
5.5 SUMMARY 
In summary, we have developed a simple RNA microfactory where synthesized RNA is 
removed from bead tethered T7 RNA polymerase and promoter DNA shortly after synthesis, 
preventing RNA rebinding and cis-primed extension activities that otherwise would produce high 






































































CONCLUSIONS & FUTURE DIRECTION 
 
RNA therapeutics have advanced significantly over the past decades and are slowly 
replacing conventional drugs (small molecules and protein replacement therapies), as discussed in 
detail in Chapter 1. The number of FDA approved RNA therapeutic therapies is increasing each 
year (106), with the most recent emergency approval coming to mRNA-based vaccines by 
BioNtech/Pfizer and Moderna (107, 108). Although the global pandemic is an especially daunting 
period globally, it has come at a time that has allowed the mRNA therapeutics approach to step up 
significantly to offer relief. This fast of an advancement was not expected, but it was made possible 
as researchers and companies exploited decades of research and knowledge to rise to the challenge.  
When compared with conventional medicine, two key advantages of RNA therapeutics are 
1) development speed and 2) application versatility. The superiority of RNA therapeutics 
development speed was clearly demonstrated in 2020, as two pioneering examples of mRNA-
based vaccines were developed in record time by parallel groups at BioNtech/Pfizer and 
Moderna/NIH to provide relief against the global Covid-19 pandemic (16, 109, 110). Moderna 
developed and initiated clinical trials of mRNA-1273 only 6 weeks from the publication of the 
genome sequence of SARS-CoV-2; a breakthrough accomplishment in record time in medicinal 
history (16, 111). Traditional vaccines have taken decades to develop, and this breakthrough 
timeline of mRNA vaccine development exemplifies the promise of RNA therapeutics in relieving 
other likely future global pandemics. The second most important advantage of RNA therapeutics 
is versatility, and this advantage can be demonstrated with an example. As viruses mutate, 
traditional vaccines developed for the original strain often fail to immunize against the mutated 
strain. Thus, in traditional vaccines, researchers need to commit to a new research and development 
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process to be able to establish a novel vaccine for the mutated strain. Whereas with mRNA 
vaccines, a completely novel vaccine need not be developed. If an mRNA-vaccine is already 
established for a target virus strain, it can be adapted to any mutated version just by changing the 
ORF region of the mRNA used in the vaccine. As soon as the genome sequence of the mutated 
strain is decoded, it could take only a week to develop the novel vaccine for the mutated strain. 
These two areas (speed and versatility) exemplify the most important advantages of RNA 
therapeutics and demonstrate how it holds the power to digitize and transform conventional 
medicine (112).  
Currently, RNA therapeutics is at the forefront of global attention due to the mRNA 
vaccine efforts. This field has advanced significantly over the past decades and is poised to rapidly 
compete with conventional drugs (i.e., biologics and small molecule drugs) for various treatments 
and vaccines due to the numerous advantages it offers (3, 113). It is poised to transform medicine 
to a versatile, digitized and more customizable position, and accordingly is expected to gain even 
more momentum in the years to come. As such, it is evident that high yields of pure RNA will be 
needed in the upcoming decades to support the rapid advancement of novel RNA therapies.  
All mRNAs and many other small RNAs are synthesized in vitro by T7 RNA polymerase 
under high yield conditions (18, 20, 23, 66). While chemical synthesis is able to generate high 
quality RNAs of up to only about 50-100 nt (with low yields and purity at the higher lengths), 
enzymatic synthesis using T7 RNA polymerase can generate high yields of RNA of all lengths. 
While this enzyme is highly promoter specific and robust, it is also known to participate in 
significant non-promoter driven activities (20, 25, 30–32, 34, 36–46). Our lab recently 
demonstrated that T7 RNA polymerase generates RNAs longer than the encoded length, through 
a cis primed extension mechanism (32). When high yields of RNA accumulate in solution, 
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polymerase binds the 3’ end of RNA and extends the RNA using the RNA as a self-template, 
resulting in a heterogeneous and distributive pool of double stranded, longer than encoded RNA 
impurities (20, 28).  
While researchers follow up in vitro T7 RNA polymerase transcription with extensive 
purification methods, along the process, they sacrifice quality and yield of the encoded RNA 
recovered (60–65). Plus, current purification methods cannot fully recover only the encoded RNA 
from a heterogeneous pool. For example, an mRNA of 3000 nt cannot be easily purified from a 
double stranded RNA impurity of 3050 nt RNA. Past reports noted that in vitro transcribed RNA 
can induce the innate immune response in therapeutics applications (62, 69, 114). This is likely 
due to the dsRNA impurities that were generated through cis primed extension and could not get 
purified with standard methods used. Especially in RNA therapeutics applications, without 
complete elimination of double stranded RNA, these impurities may activate the potentially lethal 
immune response. All in all, it is evident that the inventions in this dissertation can help in three 
major areas: 1) encoded RNA yield & scalability for the industry 2) encoded RNA purity 3) 
preventing the innate immune response in therapeutics applications.  
In Chapter 1, I described the significance and future of RNA therapies and vaccines, the 
current methods used to generate and purify high yields of encoded RNA, the origin of enzymatic 
transcription impurities in high yield reactions, and the problem with the double stranded nature 
of such impurities. This depicted a clear understanding of why there is an urgent need to update a 
more than 30-year-old enzymatic RNA generation protocol. In chapter, I will briefly summarize 
the technologies invented in Chapters 2-5 and elaborate on how each technology might be 
beneficial to different end users. I will conclude with future directions on each technology and 
how they might be integrated to various downstream applications.  
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In Chapter 2, we established a novel in vitro transcription method that inhibits product 
RNA binding, while fully retaining promoter transcription. In previous years, multiple labs 
demonstrated that partially single stranded promoter DNA (pss[-5]) binds T7 RNA polymerase 
more tightly. In this research, we used partially single stranded promoter DNA (pss[-5]) to 
strengthen promoter binding (90–92). To further eliminate the cis primed extension activity of the 
enzyme, we increased added salt concentration. Using pss[–5] drives initiation of transcription to 
better compete with cis primed extension, and increasing added salt further inhibits any RNA 
rebinding activity. Transcription is resistant to salt, and the method is universal to other sequences 
and lengths. While we only tested the method for RNA shorter than 40 nt, we expect it to be 
functional for longer RNA due to its observed ability for efficient promoter clearance. The strong 
promoter binding may impair the transition to elongation, but not at a rate that is detrimental. The 
apparent side product of this impairment is a 12-15 nt RNA, which can be easily separated from 
encoded RNA by routine purification methods. This method is relatively straightforward and low-
cost. Researchers who aim to generate short RNA and use synthetic DNA constructs can order the 
short nontemplate strand and couple it with their desired template DNA. Using high yield 
transcription buffer recipe optimized in Chapter 2 with 0.3-0.4 M added salt, they can improve 
both the purity and yield of the product RNA. We expect this method to be of great use to small 
labs in academia, and other labs in industry that routinely generate short RNA such as gRNA for 
CRISPR applications. The straightforward nature of the protocol makes it easy to implement, 
without further need to optimize conditions. 
In Chapter 3, we established another novel in vitro transcription method based on a 
fundamentally similar idea as that described in Chapter 2, but one that is functionally different. 
Transcription is carried out under high salt to eliminate RNA product rebinding, while promoter 
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DNA and T7 RNA polymerase are co-tethered in proximity on magnetic beads to drive promoter 
binding and initiation. This combination results in an increase in overall yield and purity of the 
encoded RNA. The tethered system favors promoter-directed transcription at high salt; but does 
not impair promoter clearance or elongation, unlike the method used in Chapter 2. While pss[-5] 
impairs promoter clearance, as demonstrated previously by our lab (73), tethering does not seem 
to have such effect by itself or with combination of added salt. The tethered system was shown to 
be applicable for RNA of different sequences and lengths (tested up to 40 nt in this research). 
This new system also offers dramatic improvements in encoded RNA yield and purity. 
Transcription can be repeated in batch syntheses by reusing the tethered system without significant 
loss in yield between repeats. Whilst developing the system, we found that using pss[+2], a mimic 
for full length dsDNA templates, leads to loss in overall yield in batch repeats. However, 
strengthening promoter contacts by using a pss[-5] promoter DNA leads to longer retention of 
usability in each round. Using pss[-5], the tethered system was demonstrated to be reusable over 
at least three rounds of batch transcription (the maximum attempted to date) without any 
significant loss in overall encoded RNA yield.  
Transcription with both components tethered to a solid support sets the stage for 
microfluidic reactors described in Chapter 5, but also can be used in its own right to improve 
throughput. Previous batch reactors developed by Tesla and Davis only tether DNA to the solid 
support(57, 59). Accordingly, these batch repeat systems require addition of fresh enzyme every 
round of transcription. Our system allows both DNA and T7 RNA polymerase to be reused 
multiple rounds. This will be important for cost savings in RNA production. Furthermore, those 
batch systems demonstrated by Tesla and Davis allow high yields of product RNA to accumulate 
near T7 RNA polymerase. As demonstrated previously, accumulation of RNA near polymerase 
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exacerbates cis primed extension and result in the generation of double stranded RNA impurities.  
Our system is designed to prevent the polymerase from interacting with the product RNA, ensuring 
only promoter driven transcription to take place in solution. Therefore, our system is superior in 
terms of the purity of the RNA produced as well.  
In Chapter 4, we developed a novel affinity capture method for the purification of in vitro 
transcribed RNA in high yields. We first demonstrated that immobilized DNA complementary to 
the 3’ end of the RNA can be used to selectively purify only the desired RNA from a pool of 
heterogeneous products, post transcription. Next, we improved a previously demonstrated 
methodology from our lab(47) where RNA self-primed extension is competitively inhibited using 
a similar 3’-complementary capture DNA oligo in the transcription reaction. In a new application 
we employed a biotinylated capture DNA and followed transcription by mixing the crude 
transcription reaction with streptavidin beads. While the method was successful fundamentally, 
the low capacity of the magnetic streptavidin beads posed a challenge in applying the method to 
high yield product pools.  For this reason, we tested the approach with high capacity Strep-Tactin® 
XT beads and demonstrated its ability to affinity capture high yields of product RNA in solution. 
While this study was not completed, it was shown that these beads can capture high yields of in 
vitro transcribed RNA in solution. We expect with minor optimizations along the protocol, results 
of this project can be realized in short time.  
I also developed a novel purification technology to improve the capacity of any bead used 
for affinity purification of in vitro transcribed RNA. In this novel invention, the capture capacity 
is improved by using rolling circle amplification to generate a single longer DNA containing 
multiple capture sites. While the bead binds the same molar amount of DNA, a single DNA can 
capture many product RNAs, amplifying the bead capacity. Whilst optimizing the protocol, we 
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realized that adjusting the rolling circle amplification time and conditions were crucial. Further 
optimizations are required in order to prevent tangling of the long DNA, while ensuring long DNA 
production for the purification of high yield of RNA. This project can also be integrated into the 
microfluidic chip developed in Chapter 5, in a downstream chamber, to capture only desired RNA 
and purify it in the solution of choice, free of Mg, NTPs and other biproducts of transcription. We 
expect this approach to decrease the need to follow lengthy and laborious purification steps 
implemented by current researchers in the field. 
Finally, we developed a novel universal capture DNA purification system where a 
universal DNA oligo with a fixed sequence is immobilized on beads, a dual capture DNA oligo 
with complementarity both to the universal DNA oligo and to the 3’ end of the RNA to be purified 
binds to the universal DNA oligo, and product RNA can be recovered efficiently from a 
heterogeneous pool of products. While this system had roadblocks in its use during synthesis, we 
suggest its most appropriate use to be for purification on any RNA sequence after transcription. It 
can be combined with the microfluidic chip in Chapter 5, in a manner similar to the one I 
mentioned in the previous paragraph.  
The purification methods elaborated in Chapter 4 have the potential to rapidly achieve 
purities that are currently attainable only through lower efficiency and more labor intensive 
chromatographic (or gel electrophoretic) approaches. Importantly, while the latter become more 
difficult with increasing length of the RNA, this approach should be relatively independent of 
RNA length. We expect this to be of great importance to all labs where double stranded RNA 
impurities may not be easily purified with generic purification methods, where researchers look 
for a cleaner RNA to be used for downstream applications. This might be of great importance for 
nanotechnology (i.e., DNA origami, toehold reactions) and for therapeutics applications. Its 
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combination with a microfluidic system would offer the possibility of a “one-push” closed 
system/devide for transcription and purification of any desired RNA.  
In Chapter 5, we established a novel fluidic in vitro transcription device where the tethered 
DNA-enzyme system developed in Chapter 3 is trapped inside a flow reaction chamber. As 
substrate flows into the reactor, encoded product RNA is continuously flowed away from the 
reaction chamber and collected in an Eppendorf tube. We successfully demonstrated fluidic in 
vitro transcription of encoded RNA using the pss[+2] promoter construct. Flow conditions did not 
seem to negatively impact the initiation and elongation events, allowing full transcription 
functionality of the trapped tethered system, as expected. However, as in the repeat batch reactions 
with the pss[+2] promoter construct, we observed an overall loss in transcription after 15 minutes. 
To overcome this issue, we used the pss[-5] promoter construct, which binds polymerase more 
tightly. With that, we retained transcription of the encoded RNA for about 35 minutes of run time. 
To further improve the retention of the template DNA, we tested a lower flow rate and observed 
continuous transcription for 1 hr.  Slower flow rates resulted in the product RNA accumulation 
near enzyme and resulted in increased rate of primer extended RNA products, as expected by the 
model. Future applications of this approach can adjust flow rate to balance yield vs purity. To 
further improve purity at lower flow rates, researchers can include added salt in the transcription 
buffer, as previously demonstrated to provide relief in Chapter 3. 
While repeat batch reactors have been previously described, this is the first in vitro 
transcription in a microfluidic (lab-on-a-chip) system. There are two other systems that targeted to 
automate the transcription system in literature, as demonstrated by Davis and Curevac/Tesla (57, 
59). Those systems are not considered fluidic setups; they are repeat batch reactors that aim to 
reuse the DNA component to save on cost. The limitations of these automated systems are in their 
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batch nature. In their batch reactors, they require introduction of fresh RNA polymerase with each 
batch, losing the opportunity to save on cost on reusing the enzyme. More importantly, these batch 
reactors do not alleviate the critical setback of conventional high yield in vitro RNA transcription 
protocols- which is the accumulation of product RNA near T7 RNA polymerase. It is known that 
as product RNA accumulates in a batch reactor near RNA polymerase, the enzyme  (through mass 
action) binds 3’ end of product RNA, and self-extends through a cis primed extension mechanism- 
resulting in significant yield of dsRNA impurities (31, 32). In contrast, our system 1) automates 
the manufacturing process, 2) allows all transcription components (promoter DNA and T7 RNA 
polymerase) to be reused, and 3) prevents any accumulation of RNA near polymerase, preventing 
the formation of dsRNA impurities. Initial estimations in Chapter 5 further suggest savings on 
time, as a 30 min flow reaction and a 4 hr traditional high yield batch reaction is estimated to 
generate similar RNA yields. We expect our platform to be invaluable for RNA manufacturing 
needs, where time and cost considerations are paramount, and purity is essential to success of any 
downstream need.  
The philosophy of our microfluidic transcription system resembles the lean production 
system originally implemented in Toyota car manufacturing facilities, pioneered by Taiichi Ono 
(115). While the main production philosophy of Ford manufacturing system was producing large 
quantities to save on cost, Toyota system revolutionized the approach by focusing on reducing 
overproduction and inventory management (115). They focus on eliminating waste and non-value-
added activities, and improving the overall quality of the produced item (115). While those systems 
were established for the manufacturing needs of the automotive industry, it is not difficult to apply 
these ideas to biotech (116).  
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In our research, by favoring promoter-driven transcription over non-promoter driven 
activities, we essentially eliminate wasteful production of longer, double-stranded RNA 
impurities. The revolutionary change LPS brought to car manufacturing and other fields is clearly 
demonstrated in its countless methods of implementation on production systems and management 
practices (117–119). This year, we witnessed another revolutionary manufacturing system led by 
a U.K based electric vehicle company called Arrival. In a novel approach, manufacturing is 
focused on small scale, distributed production facilities. The flexibility of their system offers the 
ability to setup tandem manufacturing cells that can be added and discarded as the need arises. 
This gives the opportunity to control production scale and offers the opportunity for facile 
customization. It also offers significant cost-savings in manufacturing, inventory management and 
production facility real estate. Most importantly, it leaves ample room for real time innovation, as 
novel components can be added to a production setup, simply with the addition of a novel cell to 
the distributed manufacturing process. 
These manufacturing pivot points in large automotive production systems can be used as 
an informative booklet to set up the stage for mass manufacturing of RNA and innovating novel 
RNA therapeutics in an automated, customizable, and highly digitized approach. The main benefits 
of RNA based therapies are digitization and customization of medicine. Accordingly, such 
manufacturing and drug development processes are paramount in this field’s continued success in 
the long term. To give an example for a future possibility, we can brainstorm what manufacturing 
and development arenas are possible, based on the new platforms we establish in this dissertation. 
It is important to note that the scope of lean RNA manufacturing platforms we establish in this 
thesis does not need to be limited for in vitro transcription. It can be used as a baseline to satisfy 
automated, efficient and scalable manufacturing needs in RNA therapies as a whole. It can also be 
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used in expanding the possibility of how next generation inventions are developed. In this new 
way of thinking, it is possible to say that lean manufacturing and automation can inform the 
scientific teams in the innovation needs, and both sectors can work hand-in-hand, constantly 
talking to each other and improving with information gathered at both sections. This will be the 
new age of innovation, where innovation is not only conceived by scientists in lab, but a new 
direction where continuous improvement strategies are conceived collaboratively with research 
and development, manufacturing and management teams. The future possibilities of what is 
established in this dissertation then, are three tiered: manufacturing, distributed production 
(improved distribution) and novel therapy development.  
First, in its manufacturing capability, high yields of RNA can be produced in a systematic, 
controlled, scalable and highly reproducible fashion. The microfluidic device can be connected to 
other downstream microfluidic or fluidic setups. For instance, in the case of producing an mRNA 
vaccine, the manufacturing facilities rely heavily on manual handling that require highly trained 
technical staff. They also need to adhere to strict Good Manufacturing Practices (GMP) regulations 
(112, 120). As a result, current manufacturing processes are costly, laborious, time consuming and 
take up significant space in house manufacturing facilities. Many DNA templates to be used for 
mRNA production are generated in house, starting with the preparation of plasmid DNA, followed 
up with transcription, purification, 5’ and 3’ capping, and encapsulation in optimized delivery 
vehicles (112). Our microfactory platform offers an opportunity to automate this entire process in 
massively parallel, tandem microfluidic devices. For instance, in this research, we demonstrated a 
continuous flow system for the high yield generation of encoded RNA without the double stranded 
impurities. In an alternative system, our setup could be used to develop an automated system for 
the incorporation of modified bases selectively or throughout the RNA. With the prevention of 
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dsRNA generation, there should not be a need for incorporating synthetic nucleotides (e.g., pseudo 
(ψ)-UTP), but if needed the system would be fully compatible with the use of such modified bases. 
For mRNA vaccines, 5’ and 3’ capping could be implemented post transcription downstream the 
flow transcription within a tandem microfluidic chip, or cotranscriptionally within the setup 
developed here. Furthermore, the platform can be combined with other downstream microfluidic 
devices to prepare the RNA for vaccines or therapies in the optimized delivery vehicle of choice. 
This way, from transcription of RNA to final drug preparation in the desired delivery format, all 
processes can be combined in an automated, microfluidic setup in a cheap and versatile manner. 
This would offer enormous flexibility on what can be produced in a microfactory. A new microchip 
could be developed separately, and added in tandem to the production line, when needed to further 
customize the produced RNA or therapy for customer’s need. 
The core idea here is a distributed microfactory approach where series of tandem 
microdevices can be brought to different production sites (i.e., clinics) and only the desired product 
at required yields can be produced with superior purity and quality. This, in its essence is similar 
to the core idea of the LPS system, as no production is unintended, and only what is desired is 
produced with excellent quality. If we add in the flexibility of distributed manufacturing ideology 
implemented by Arrival EV for car manufacturing, we can envision an ultimately superior drug 
manufacturing platform for the RNA therapeutics industry. All in all, the microfluidic automated 
system would streamline manufacturing processes and allow for its use at any hospital/company 
set up in a facility of choice. The enclosed fluid path, scalable production system, automated use 
and flexible addition/separation of tandem components are all attractive points to lower labor and 
manufacturing cost from a supplies chain standpoint. This platform can decrease the need for 
manual intervention, and set up the stage for a streamlined, automated manufacturing setup.  
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Second, following the example of the generation and distribution of an mRNA vaccine, 
there remains the challenge to distribute the vaccine to the world at large. With the generic 
production systems used, companies make abundant products at home manufacturing facilities and 
distribute them to partner facilities throughout the world, within temperature-controlled systems. 
Such systems add up to the cost and pose novel constraints in the supply chain, such as the 
requirement for dry ice and storage containers, the reliability of shipping and delivery (112). The 
idea of an automated tandem microfluidic set up that can generate an mRNA vaccine from 
transcription to encapsulation within an optimized delivery path, then, is one that can alleviate 
these steps. With a streamlined microfluidic setup, such a microfluidic setup could be distributed 
to the world for production of vaccines at the delivery site, according to the need. This further 
supports the idea of a lean manufacturing system where only the required amount of RNA is 
produced for the required need of vaccines at the location of manufacturing.  
Third, from a novel therapy development lens, our platform sets the stage for its ability to 
offer the production of a vast number of therapeutic leads to be tested. In tandem chips, different 
RNAs can be generated, and combined with a number of delivery vehicles, creating a library of 
therapy candidates. It would make the lead selection process streamlined, automated and with the 
abundant selection catalog would set the stage for developing a successful RNA therapy. Since 
RNA therapeutics can be applied for a vast number of diseases, the factories then offer the 
possibility to enhance this field and bring novel therapies to clinic in short time. Only with such a 
production and development system, RNA therapeutics field can reach the digitized, versatile and 
customizable feature envisioned. 
The global pandemic has pushed the RNA therapeutics industry to step up significantly. 
We are now in a place to apply decades of knowledge to bring RNA therapeutics into the clinic. 
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With this new era, it is not sufficient to generate some quantities of RNA in lab, follow up with 
extensive purification protocols and prepare for their drug delivery vessel in separate workstations. 
We are now at a place where high yields of RNA are needed to be manufactured at large quantities 
in an automated and streamlined manner. We expect our novel RNA microfactory platform to 
disrupt the current RNA manufacturing processes and set the stage for novel therapy development 
strategies. The future of digitized and customizable RNA therapeutics is here and can be exploited 
if we can make the most the automated, clean manufacturing approaches developed in this 
dissertation and use our system to develop massively parallel microfluidic RNA production and 
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